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Tuberculosis (TB) is a major cause of death worldwide. Control of Tuberculosis is a
serious challenge to global health. A new and potentially devastating threat to TB
control is the emergence of multi-drug resistant TB (MDR-TB). South Africa was
ranked fourth among the countries with the highest number of confirmed MDR-TB
cases.
Aim
The aim was to investigate the annual MDR-TB prevalence and associated risk
factors for MDR-TB from 2001 to 2007 at the Prince Cyril Zulu Communicable
Disease Centre. To investigate previous TB treatment duration, previous TB
treatment outcome, and duration of previous TB treatment interruption in a subgroup
of patients who were previously treated for TB. To determine the average length of
time from diagnosis of TB to diagnosis of MDR-TB and commencement of MDR-TB
treatment.
Methods
An observational analytic nested case-control study design was used. All patients
who were diagnosed with pulmonary TB and who had a sputum culture performed
between 2001 and 2007 were included in the study. The cases were all MDR-TB
cases diagnosed on sputum culture between 2001 and 2007. The controls were
drug susceptible TB cases which had a sputum culture done at diagnosis, and were
diagnosed in the same month as the MDR-TB case
Results
There were 10 205 sputum cultures performed from 2001 to 2007. MDR-TB was
found in 445 patients. An increase in the prevalence of MDR-TB occurred in 2007,
due to a significant increase in prevalence among new TB cases. The MDR-TB
prevalence was 11.7% among new TB cases and 4.7% among previously treated
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TB cases in 2007. There was no significant association between demographic
characteristics and MDR-TB. Previous TB treatment failure and a duration of
previous TB treatment of greater than 32 weeks was found to be significantly
associated with MDR-TB. The median time from TB diagnosis to MDR-TB diagnosis
was 98 day and from MDR-TB diagnosis to MDR-TB treatment 10 days.
Discussion
Delays in the diagnosis of MDR-TB, long waiting times before MDR-TB treatment
commencement and lack of isolation have contributed to the spread of primary
MDR-TB and was most likely responsible for the increase in prevalence of MDR-TB
among new TB cases.
Recommendations
It was suggested that a sputum specimen should be obtained for culture and
sensitivity from all new TB patients in areas which have an MDR-TB prevalence of
greater than 3% among new TB patients.
Ensure patient education on basic infection control measures.
Improve MDR-TB diagnosis and reduce waiting times for MDR-TB treatment.
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Tuberculosis (TB) is a major cause of death worldwide. Globally the incidence risk
for TB was 139 per 100 000 population in 2007.1 An estimated 20 deaths per
100 000 population occurred globally in  2007 among Human Immunodeficiency
Virus (HIV) uninfected incident TB cases.1 There were 456 000 (33%) deaths among
HIV infected incident cases of TB.1 South Africa was ranked fifth among the 22 high
burden tuberculosis countries in terms of overall TB burden in 2007.1 Among the 15
countries which had the highest estimated TB incidence per capita, South Africa was
ranked second in 2007.1 The Internationally recommended directly observed
treatment, short course (DOTS) strategy was implemented in South Africa in 1996
after TB was declared a national emergency. 2 Despite these efforts, TB incidence
and case-fatality  have increased threefold in South Africa during the decade from
1994 to 2004.3 More than 400 000 cases of TB are treated annually in South Africa
but only 60% are cured.1
Control of TB is a serious challenge to global health. A new and potentially
devastating threat to TB control is the emergence of multi-drug resistant TB (MDR-
TB).4 MDR-TB is defined as, “resistance to isoniazid and rifampicin”3 (the two most
potent anti-TB drugs).
Multi-drug resistant tuberculosis was identified as a problem in all the regions under
the World Health Organization (WHO) surveillance. MDR-TB isolates constitute 1 to
3% of global isolates.7 Each year over 400 000 people develop MDR-TB world wide.
In 2007 among the 10.4 million cases of TB globally, an estimated 4.9% or 511 000
were cases of MDR-TB. Of these 511 000 cases of MDR-TB, 289 000 were among
new cases (3.1% of all new cases) and 221 000 were among cases that had been
previously treated for TB (19% of all previously treated cases).1  According to the
WHO, in 2007 South Africa ranked fourth among the 30 countries with the highest
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number of MDR-TB cases.1 South Africa reported the highest number of confirmed
MDR-TB and extensively drug resistant tuberculosis (XDR-TB) cases in the African
region.1 The prevalence of MDR-TB in South Africa in 2007 was 1.8% among all
new TB cases and 6.7% among previously treated TB cases.1
MDR-TB can be as a result of failure of drug sensitive TB treatment with
development of resistance (acquired MDR-TB) or as a result of direct transmission
of a multi-drug resistant strain (primary MDR-TB).5 The development of MDR-TB,
with subsequent transmission of drug resistant strains in the community, may be the
result of many factors. Globally, these factors have included  programme related
factors such as inadequate management of patient’s treatment, absence of directly
observed treatment, shortages of drug supply, suboptimal drug quality, uncontrolled
availability of anti-tuberculosis drugs without prescription, lack of uniformity between
the public and private health sector treatment guidelines , and poorly managed and
supported national TB control programmes.6.  In addition, patient characteristics
including age, HIV infection and poor adherence to treatment have also been
implicated to influence the transmission of drug resistant organisms.
Multi-drug resistant tuberculosis is difficult and expensive to treat. The economic
burden of this problem is already evident in South Africa where in 2009, the drug
costs for treating a case of drug susceptible TB was R110 in comparison to the drug
costs for treating a case of MDR-TB was which was R1866.9 In South Africa in 2009,
the average district hospital cost per MDR-TB patient per day was R850 and the
average regional hospital or MDR-TB hospital cost per MDR-TB patient per day was
R1100.10 These hospital costs exclude drug costs. The cost of community based
injection teams was estimated to be R86 per day excluding the cost of drugs.1
Patients with MDR-TB remain infectious for much longer, both in the community and
in hospital.11 In addition to this, patients need to be hospitalized for much longer
1 Community based injection teams is based on the on the Church of Scotland Hospital model which
uses four injection teams to manage thirty patients. The cost includes the salaries of staff, running
costs of vehicle, and the purchase price of vehicle built in on a three year purchase amount. The cost
excludes the cost of drugs.
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periods of 4 to 6 months and treatment is required for up to 24 months.12 Less
effective and more toxic second line drugs have to be used to treat MDR-TB11 Many
laboratory investigations are required (monthly bacteriology cultures) and drug
toxicity necessitates additional laboratory screening tests such as liver and kidney
function tests.12  MDR-TB often culminates in incurable disease.7 The MDR-TB
case-fatality is estimated to range from 40% to 60%, which is similar to the mortality
of patients with untreated tuberculosis.7
The problem of MDR-TB is further compounded by the current HIV epidemic.25 A
systematic review of studies assessing HIV infection and risk factors for MDR-TB
found that  in a study in the United Kingdom, MDR-TB patients who were HIV
infected were nine times more likely to die than those who were HIV uninfected, and
in a study in Peru, 50% of MDR-TB patients who were HIV infected died.5 The
systematic review reported that several countries with longer follow-up observed
case-fatality ranging from 72% to 89% in patients co-infected with MDR-TB and
HIV.5 In South Africa it was estimated that 55% of drug susceptible TB cases and
60% of MDR-TB cases were co-infected with HIV.13
Table 1: TB treatment outcomes for South Africa 2006 – 2007 (n = 182 741)
New smear positive Re-treatment smear
 TB cases positive TB cases
Number of smear positive TB
cases 139 516 43 225
TB Treatment outcome (%)
Cured 63 56
Treatment completed 11 10
Died 7.3 5.1
Treatment failed 1.7 9
Treatment defaulted 9.1 12




In South Africa, in 2006 there were 139 516 new sputum smear positive and 43 225
re-treatment smear positive TB cases registered in the DOTS programme nationally.
These cases were followed up through 2007.  The reported treatment outcomes in
the cohort of new cases found that 63% of cases were cured, a further 11% of cases
completed treatment, but were not proven to be cured, 7.3% of TB cases died, 1.7%
of cases failed treatment and 9.1% of cases defaulted TB treatment (Table 1).  The
TB treatment outcomes in the cohort of re-treatment cases found that 56% of cases
were cured, 10% of cases completed treatment, 5.1% of cases died, 9.0% of cases
failed treatment and 12% of cases defaulted treatment.1 (Table 1)
One of the objectives of tuberculosis control programmes is to minimize the
emergence of drug resistance. In South Africa, due to limited resources the National
Tuberculosis Control Programme does not recommend sputum culture and drug
susceptibility testing for all TB patients. Drug susceptibility testing is used selectively
for patients at risk for MDR-TB. Culture and drug susceptibility testing is
recommended for the following groups of patients14:
 All re-treatment TB patients;
 New TB patients who remain sputum smear-positive after two months (new
cases) or three months (re-treatment cases) of first-line treatment;
 Symptomatic close contacts of confirmed MDR-TB patients; and
 Symptomatic patients from known high risk groups, including health care
workers, laboratory workers, prisoners and HIV infected patients.
This study was conducted at the Prince Cyril Zulu Communicable Disease Centre,
situated in the centre of the city of Durban in the province of KwaZulu-Natal, South
Africa. The Prince Cyril Zulu Communicable Disease Centre provides outpatient
services which include investigation, diagnosis and management of patients with TB,
and sexually transmitted infections. Voluntary counseling and testing for HIV (VCT)
services are also provided at the Prince Cyril Zulu Communicable Disease Centre.
The centre does not serve a well defined catchment population. The Prince Cyril
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Zulu Communicable Disease Centre is situated adjacent to the taxi rank which is the
main transport node for the city. It therefore provides services to the entire
eThekwini Metropolitan Municipality. Walk-in patients and patients referred from
primary health clinics and hospitals are accepted at the centre. Patients with MDR-
TB are diagnosed at the Prince Cyril Zulu Communicable Disease Centre and then
referred to the hospitals designated to manage MDR-TB for therapy. There are an





















































2001 2002 2003 2004 2005 2006 2007
TB cases
New Cases Relapses After Default After Failure All other Retreatment Cases
Figure 1: Number of pulmonary tuberculosis cases registered at Prince Cyril
Zulu Communicable Disease Centre from 2001 to 20072
2 Information was sourced from the Prince Cyril Zulu Communicable Disease Centre database.
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The number of patients with pulmonary TB diagnosed and managed at the Prince
Cyril Zulu Communicable Disease Centre had decreased from 5096 in 2001 to 3504
in 2007 (Figure 1). This decrease was due the decentralization of TB services to
Primary Health clinics. Patients were referred to their local primary health clinics
before registration. The Prince Cyril Zulu Communicable Disease Centre registers
over 3000 pulmonary TB cases annually. In 2007 the Prince Cyril Zulu
Communicable Disease Centre registered 3514 pulmonary TB cases, 62% of smear
positive cases were new cases and 38% were re-treatment cases. From the smear
positive re-treatment cases 22% were relapses, 23% after defaulting treatment and
1.9% after having failed treatment.
The trend in TB treatment outcomes at the Prince Cyril Zulu Communicable Disease
Centre from 2001 to 2007 (Figure 2) showed that the proportion of all TB cases
successfully treated had improved to 63% among cases who commenced treatment
in 2007. Sixty per cent of the new smear positive cases were cured in 2007, which
was compatible to the national cure rate of 63% in 2007.1The treatment failure rate
at the Prince Cyril Zulu Communicable Disease Centre was 1.7% in 2007, which
was similar to the national treatment failure rate of 1.7% in 2007.1 In 2007, 25% of
new smear positive TB cases defaulted treatment. The Prince Cyril Zulu
Communicable Disease Centre has had a consistently high number of cases
defaulting from treatment which was more than twice the national treatment defaulter
rate of 9.1% in 2007.1 Among the re-treatment smear positive cases (Figure 3), 52%
of cases were cured in 2007. This was slightly lower than the national cure rate of
56%.1 The Prince Cyril Zulu Communicable Disease Centre has had improvement in
cure rates over the seven year period, but for both new and re-treatment cases the
cure rates at the Prince Cyril Zulu Communicable Disease Centre remain below the
target for South Africa which is 85%.18 In 2007, 2.2% of re-treatment smear positive
cases failed treatment, this was lower than the national treatment failure rate of 9%
in 2007. 1 The Prince Cyril Zulu Communicable Disease Centre has had a
consistently high number of treatment defaulters among re-treatment cases. In 2007,
31.3% of re-treatment cases defaulted from treatment. This was much higher than





















2001 2002 2003 2004 2005 2006 2007
TB Treatment Outcomes from 2001 to 2007
Treatment success Treatment Failure Died during treatment
Defaulted from treatment Transferred to another unit Patients not evaluated
Figure 2: Number and category of TB treatment outcomes for all TB cases at













































































































































2001 2002 2003 2004 2005 2006 2007
TB Treatment Outcomes for New and Re-treatment Smear Positive Cases from 2001 to 2007
- cured Treatment completed Treatment failure - Died during treatment
- Defaulted from treatment Transferred to another unit Patients not evaluated
Figure 3: Treatment Outcomes for New and Re-Treatments Smear Positive Cases at
the Cyril Zulu Communicable Disease Centre from 2001 to 20072
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1.3. THE PROBLEM
The problem is MDR-TB. The prevalence of MDR-TB varies considerably throughout
the world and between regions, with outbreaks isolated to some areas and
institutions. There is limited epidemiological data on patients with MDR-TB from
most of the developing world. In South Africa, the prevalence of MDR-TB varies
between provinces. The burden of MDR-TB at district or facility level is relatively
unknown. KwaZulu-Natal was the province with the highest TB caseload in 2006,
accounting for 31% of all TB cases nationally.15 The eThekwini district in KwaZulu-
Natal was identified as one of the four districts which have a quarter of the national
TB caseload. 16 The Prince Cyril Zulu Communicable Disease Centre is a facility with
one of the highest TB caseloads. MDR-TB cases have been identified at this facility
but the extent of the problem of MDR-TB is unknown. MDR-TB is an infectious
condition with associated morbidity and mortality. The burden of MDR-TB needs to
be quantified and factors that are contributing to the development and spread of
MDR-TB need to be determined. A greater understanding of the scale of the
problem would enable appropriate interventions to improve diagnosis and reduce
transmission of MDR-TB.
1.4. AIM
This study aimed to investigate the annual MDR-TB prevalence and associated risk




The primary objectives of the study were:
1. To describe the annual trend in MDR-TB prevalence from 2001 to 2007 at the
Prince Cyril Zulu Communicable Disease Centre, eThekwini;
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2. To identify and describe the association between demographic
characteristics, a past history of previous TB treatment, HIV status, referral
type and an outcome of MDR-TB; and
3. To determine the mean length of time from TB diagnosis to MDR-TB
diagnosis and MDR-TB treatment commencement.
Secondary Objectives (Subgroup analysis of MDR-TB and TB patients with a
history of previous TB treatment)
The secondary objectives were:
a. To identify and describe the association between previous TB treatment
duration, previous TB treatment outcome, duration of previous TB treatment
interruption and an outcome of MDR-TB.
b. To establish the mean length of time from previous TB diagnosis to current
MDR-TB diagnosis.
Hypothesis
 There is a significant association between risk factors, namely: demographic
characteristics, a history of previous TB treatment, HIV status, referral type
and MDR-TB.
 There is a significant association between risk factors from previous TB
treatment, namely: previous TB treatment outcome, previous TB treatment
duration, previous TB treatment interruption and MDR-TB.
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1.6. DEFINITIONS
Multi-drug resistant TB (MDR-TB)
“Multi-drug resistant tuberculosis is defined as Mycobacterium tuberculosis where
there is in vitro resistance to at least isoniazid and rifampicin with or without
resistance to any other tuberculosis drugs.” 18
Extensively drug resistant TB (XDR-TB)
“MDR-TB in association with in vitro resistance to any of the fluoroquinolones plus
one or more of the injectable second line TB drugs.”15
New case of TB
“A patient who has never had treatment for TB or who has taken anti tuberculosis
drugs for less than four weeks.”18
Re-treatment case
“A patient who has taken treatment for TB before and either relapsed, defaulted or
had treatment failure.”18
Treatment failure
“A pulmonary TB patient who is still sputum smear positive at the end of the
standard treatment period.”18
Treatment default
“A patient who completed at least one month of treatment, and returns after having
interrupted treatment for two months or more.”18
Drug sensitive TB
“Mycobacterium tuberculosis that is sensitive to all anti-TB drugs.” 18
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Pulmonary TB
“Pulmonary tuberculosis refers to disease involving the lung parenchyma.”18
Extra-pulmonary TB
“Extra-pulmonary tuberculosis covers all forms of tuberculosis in which the disease
process occurs outside the lung parenchyma.”18
Primary resistance
“Resistance in cultures from patients with no history of previous tuberculosis
treatment.”19
Acquired resistance
“Resistance in cultures from patients with one or more previous tuberculosis
treatment episode totaling more than one month.”19
Treatment interruption
“Treatment interruption was defined as a patient whose treatment was interrupted for
more than two consecutive months before the end of the treatment period.15
Cure
“Client who is smear negative at, one month prior to the completion of treatment,
and also on at least one previous occasion at least 30 days prior” 15
Treatment completed
“Client who has completed treatment but does not meet the criteria to be classified
as cured or treatment failure”15
Died
“Client who dies for any reason during the course of TB treatment.”15
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1.7. SUMMARY OUTLINE PER CHAPTER
This dissertation is presented in the form of six chapters. A short description of each
chapter is outlined below:
Chapter 1
In chapter 1 an introduction to the study is given and the importance of MDR-TB is
outlined. In this chapter the background for the study is provided, the problem and
purpose of the study are highlighted. The primary and secondary objectives of the
study are stated in chapter 1.
Chapter 2
In chapter 2 a review of the literature is provided. In this chapter a theoretical review
of the development of drug resistance is given. An empirical review of other studies
on the prevalence of MDR-TB and the risk factors associated with MDR-TB is
included
Chapter 3
In chapter 3 the methods undertaken to conduct the research are outlined. The
study design, study population, data collection and sampling method are explained.
The statistical methods used to analyze the data are described in chapter 3.
Chapter 4
In chapter 4 the results are presented in the form of graphs and tables. It reports on
the findings of the study and the significance of the results obtained is discussed.
Chapter 5
In chapter 5 the results that were presented in chapter 4 are analyzed. Comparison
of the results is made with results from other studies.  The findings are discussed in
relation to the national and provincial picture.
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Chapter 6
In chapter 6 the conclusions that are drawn from the research study are provided. In
this chapter recommendations that are specific to the Prince Cyril Zulu
Communicable Disease Centre and general recommendations that can benefit TB
control initiatives are offered. Suggestions for further research are made.
1.8. CHAPTER SUMMARY
In this introductory chapter a background to the problem of TB and the development
of MDR-TB was provided. MDR-TB, its importance and associated morbidity and
mortality was discussed. The status of TB at the Prince Cyril Zulu Communicable
Disease Centre from 2001 to 2007 was described. The aims and the objectives of
the study were stated and a brief outline of the content of the chapters that will follow
was given.
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CHAPTER 2. LITERATURE REVIEW
2.1. INTRODUCTION
A review of the literature was undertaken to provide an understanding of the
development of tuberculosis drug resistance and the extent of multi-drug resistant
tuberculosis globally, regionally and in South Africa. There are many factors that
contribute to the development of tuberculosis drug resistance including client related
and management factors. Previous studies have investigated various risk factors, to
test their association with MDR-TB. The risk factors that are relevant to South Africa
and the Prince Cyril Zulu Communicable Disease Centre, specifically, are explored
in this chapter.
2.2. THE HISTORY OF DRUG RESISTANCE
Reports on TB drug resistance started more than 60 years ago, shortly after the use
of the first TB drugs commenced.39 By 1961 there were tests available for detecting
drug susceptibility.39 During the 1960s, “the common feature of data from developing
countries was a much higher prevalence of drug-resistant TB than in developed
countries.” 39 With the introduction of rifampicin and short-course chemotherapy, a
decrease in TB was seen during the 1970s which resulted in may countries stopping
TB drug resistance surveillance.39 There was an increase in TB in the 1980s with
associated outbreaks of MDR-TB mainly attributed to, “HIV and deteriorating TB
programmes” 39 Global TB drug resistance surveillance projects were initiated in
1994. 39
2.3. MECHANISM OF TURBERCULOSIS DRUG RESISTANCE
2.3.1. Natural Resistance
Spontaneous slow mutation can occur in the genome of Mycobacterium tuberculosis
leading to the development of resistant mutant organisms.20 The phenomenon of
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spontaneous mutation is genetically determined and varies from drug to drug.14 With
regard to anti-tuberculosis drugs the probability of spontaneous resistance to
isoniazid is 1 in every 106 cell divisions and the probability of spontaneous
resistance to rifampicin is 1 in every 109 cell divisions. 14 It is not common for
spontaneously occurring multi-drug resistance to occur because the chromosomal
loci responsible for resistance to different drugs is not linked.14  For MDR-TB to
occur a double spontaneous mutation to both isoniazid and rifampicin has to occur.
The probability of spontaneous resistance to both isoniazid and rifampicin is 10-15
because the probability of spontaneous mutation resulting in resistance to isoniazid
is 10-6 and the probability of a spontaneous mutation to rifampicin is 10-9. The risk of
spontaneously developing resistant mutants is very low because a large bacterial
load which  occurs in lung cavities is required for MDR-TB strains to emerge.14
Primary resistance refers to “resistance in cultures from patients with no history of
previous tuberculosis treatment”.19
Acquired resistance
“Drug resistance occurs as a result of selection of resistant mutants in the bacterial
population, due to killing of susceptible bacilli by tuberculosis drugs.”19 Suboptimal
anti-TB treatment has been implicated as a contributor to the selection of resistant
mutants. This situation can arise when monotherapy is used, either as result of
ingestion of a single anti-tuberculosis drug or from the ingestion of a combination of
drugs where the minimal inhibitory concentration of only one drug may be optimal.19
The result is that susceptible bacteria are killed rapidly and the resistant mutants are
then able to multiply.19 Resistance to rifampicin can develop within 2 to 5 months
and resistance to streptomycin can develop within 45 days. 19 “Acquired resistance
refers to resistance in cultures from patients with one or more previous tuberculosis
treatment episode totaling more than one month.” 19
2.3.3. Exogenous Re-infection
One study suggests that in an area with a high TB incidence and a high prevalence
of HIV infection, combined with the lack of airborne infection control measures,
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resistance due to exogenous re-infection is an important mechanism for the
development of MDR-TB.38 A study in KwaZulu-Natal, South Africa identified
patients who developed MDR or XDR-TB after initially being diagnosed and treated
for a less resistant form of TB. The study used spoligotyping to compare TB isolates
obtained at the time of treatment initiation with follow-up isolates that were identified
as MDR-TB or XDR-TB.  The study found that 74% of patients who developed MDR-
TB or XDR-TB, did so as a result of exogenous re-infection with a drug-resistant TB
strain (primary resistance) rather than the result of inadequate drug therapy
(acquired drug resistance). 38
Table 2: Countries with the of the highest numbers of estimated MDR-TB
cases in 2007
Number of Proportion of MDR-TB Proportion of MDR-TB among
MDR-TB Cases among new TB cases (%)
previously treated TB cases
(%)
Country
India 99 639 2.8 17
China 76 154 5 26
Russian Federation 31 397 13 49
South Africa 10 708 1.8 6.7
Bangladesh 7 694 3.5 20
Source: Global Tuberculosis Control – Epidemiology, Strategy and Financing, World health
Organization, 2009
2.3. PREVALENCE OF MDR-TB
Global
Estimates of the burden of MDR-TB are provided by the World Health Organization
(WHO) Global Project on Drug Resistance Surveillance.1The information about the
proportion of TB cases with MDR-TB was obtained from drug susceptibility testing of
samples from patients in whom MDR-TB was diagnosed in public health facilities.1
Data was available for new TB cases for 113 countries and for TB re-treatment
cases for 102 countries. 1 India, China, Russian Federation; South Africa and
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Bangladesh ranked from first to fifth in terms of the highest numbers of estimated
MDR-TB cases in 2007(Table 2).  Of the 511 000 estimated MDR-TB cases, South
Africa had 10 708 MDR-TB cases (1.8% MDR-TB among new TB cases and 6.7%
MDR-TB among previously treated TB cases).1The proportion of MDR-TB among
new cases was much lower in South Africa compared to the other countries
(Table2). Earlier literature had reported that MDR-TB isolates constitute 1 to 3% of
global isolates.7 The findings of the WHO surveillance in 2007 estimated that 4.9% of
global isolates were MDR-TB.1
The population weighted mean3 of MDR-TB among all TB cases from 114 countries
that reported to a global project was 5.3% (95% CI: 3.9 to 6.6), but ranges from 0%
in some Western European countries to over 35% in some countries of the former
Soviet Union.21
Data from India found that the prevalence of primary MDR-TB varied between 0 to
5% and for acquired MDR-TB it was between 9.6 to 80.6%.7 A study conducted in
the Lucknow District in India found that the prevalence of MDR-TB was 20%  (n =
686), primary and acquired being 13,2% (95% CI: 9.5 to 16.9) and 25% (95% CI: 21
to 30) respectively.7 These results for the Lucknow district varied considerably from
the national MDR-TB prevalence of 2.8% among new TB cases in India. Another
study in Chennai, India detected an MDR-TB prevalence of 34% (n = 618).22 .An
expanded global survey on tuberculosis drug resistance found that the prevalence of
MDR-TB in the Zhejiang Province, China was 4.5% and 10.8% in the Henan
Province, China.23 The prevalence of MDR-TB in Tomsk, Russia was 6.5% and in
Ivanova, Russia 9.0%.23
3 The drug resistance among all TB cases was reported for countries conducting routine surveillance.
In the majority of survey settings the number of previously treated TB cases was small and did not
reflect the proportion of re-treatment cases within the TB programme. Therefore when estimating
proportions of resistance among combined cases proportions were weighted by their population
within the TB programme.
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Africa
The MDR-TB case load and prevalence varies within regions of the WHO, including
the African region. South Africa had the largest number of confirmed MDR-TB and
XDR-TB cases (10 708) in Africa in 2007.1 South Africa’s neighbouring countries
Botswana, Lesotho and Swaziland had less than 150 cases each of MDR-TB in
2007.  Namibia had 270 MDR-TB cases, Mozambique 1464 MDR-TB cases and
Zimbabwe 1620 MDR-TB cases.1
In the Global MDR-TB and XDR-TB Response Plan (2007 to 2008), WHO estimated
a 2% prevalence of MDR-TB for the African region as a whole, with Cote D’Ivoire,
Democratic Republic of the Congo and Mozambique showing much higher
proportion of TB drug resistance.8 The low prevalence of resistance was fairly
consistent in WHO surveys, however, it was likely that smaller epidemics of MDR-TB
were going undetected due to poor laboratory capacity.8 The MDR-TB epidemic in
Tugela Ferry, a district in KwaZulu-Natal, South Africa is evidence of these smaller
epidemics of MDR-TB in the African region.29 At a hospital in Tugela Ferry 41% of
544 TB patients had MDR-TB.33
A study in Rwanda found that 3% of 616 new TB cases had MDR-TB and 9.4% of
85 previously treated TB cases had MDR-TB.24 In the West African country of Benin,
the prevalence of MDR-TB was 1.6% in new TB cases (n = 244) and 11.1% in
previously treated TB cases (n = 226).24
South Africa
A national survey of TB drug resistance commissioned by the National Department
of Health between 2001 and 2002 was conducted by the Medical Research Council.
In South Africa the overall prevalence of MDR-TB in 2002 was 2.9% (n = 4 358),
arising from 1.6% in new cases and 6.6% in previously treated TB cases.4 Provincial
differences in drug resistance ranged from 1.0% to 2.7% in newly diagnosed TB
cases and from 4.0% to 13.9% in TB re-treatment cases.4
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In 2006, KwaZulu-Natal was the province with the highest total TB caseload,
accounting for 31% (n = 342 315) of all TB cases in South Africa.15 A study
conducted at a TB referral hospital in Durban from 1998 to 2001 found that the
proportion of MDR-TB patients admitted rose from 7.6% (n = 740) in 1998 to 14% (n
= 1212) in  2001.26
The national survey of TB drug resistance also provided a report for each province.
The survey of tuberculosis drug resistance in KwaZulu-Natal found that the total
MDR-TB caseload for KwaZulu-Natal in 2001 was estimated to be between 1385
and 2616 cases consisting of 538 to 1016 new cases and 847 to 1600 re-treatment
cases.35 The prevalence of MDR-TB in KwaZulu-Natal n 2001 was 1.7% among new
cases and 7.7% among patients with a prior history of TB treatment.35 With regard to
MDR-TB prevalence among new cases, KwaZulu-Natal (1.7%) was the province
with the fourth highest MDR-TB prevalence. Mpumalanga (2.6%), Limpopo (2.4%)
and North West Province (2.2%) were the three provinces with the highest MDR-TB
prevalence among new cases. With regard to MDR-TB prevalence among
previously treated TB cases, KwaZulu-Natal (7.7%) was the province with the
second highest MDR-TB prevalence. Mpumalanga was the province with the highest
MDR-TB prevalence of 13.7% among previously treated TB cases.25 KwaZulu-Natal
was however the province with the highest estimated MDR-TB burden based on
cases.25
A study conducted at a TB referral hospital in Durban from 1998 to 2001 found that
the proportion of MDR-TB patients admitted rose from 7.6% (n = 740) in 1998 to
14% (n = 1212) in 2001. 26
2.5. MDR-TB INCIDENCE
There is a very high incidence of tuberculosis in the African region which suggests
that the number of MDR-TB cases within the population and the consequent risk of
transmission may also be high.4 The WHO Global Surveillance Project reports that
the prevalence MDR-TB and the incidence of MDR-TB remains largely unknown.4
Zager and McNerney (2008) did a re-analysis of the WHO Global Surveillance
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Project  data and calculated estimates of the incidence of MDR-TB in previously
untreated cases.4 Data from 97 geographical settings was compiled and it was found
that  25 settings had an estimated incidence of greater than 3 per 100 000. 4
Karakalpakstan had the highest estimated incidence of MDR-TB (35 cases per 100
000), Kazakhstan was second (22 cases per 100 000), Mpumalanga Province
(South Africa) was third (15 cases per 100 000) and KwaZulu-Natal Province (South
Africa) had the fourth highest (14 cases per 100 000) estimated incidence of
transmitted MDR-TB. 4 Countries like South Africa with high MDR-TB incidence
should prioritize measures to address the control of MDR-TB transmission.
2.6. FACTORS CONTRIBUTING TO MDR-TB IN SOUTH AFRICA
Many factors have been implicated as contributing to the development of MDR-TB.
According to the South African National Tuberculosis Guidelines, “MDR-TB is
considered to be a man-made problem, which has arisen because of human error
resulting in the poor management of drug supply, poor client management and other
client related factors.”15 These contributory factors are explored below. 15
Uninterrupted Drug Supply
The most common errors observed in the management of drug supply were15:
 Poor management of supply of first line anti-tuberculosis drugs due to poor
stock management and / or procurement problems. 15,19
 Use of tuberculosis drugs (or drug combinations) of unproven
bioavailability.15,19
The use of single first line drugs instead of fixed-dose combination tablets.15 Single
first line drugs were used in South Africa until 1999/2000, this enabled patients to
discontinue individual drugs that were causing side effects. 26
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Poor Client Management
Health system failures that lead to poor client management, inadequate or
inappropriate treatment and poor adherence all contribute to MDR-TB, including15:
 Uncaring and unfriendly staff attitudes.15,19  Lack of support and failure  to
adopt a problem solving approach to address challenges contribute to poor
relationships between clients and health care workers.15
 Poor counseling of client’s resulting in a lack of knowledge and poor
understanding of what is expected of the client. 15,19
 Ineffective systems, including absence of directly observed therapy,
unsupervised clients, poor referral, inadequate record keeping and follow-up
of clients.15
 Insufficient or absent contact tracing and follow-up of MDR-TB cases. 15
 Low staff morale, lack of regular support and supervision and low
accountability of staff for programme outcomes. 15,19
 Prescription errors including1:
o The use of two or three drugs when four or five first line drugs should be
used; 15,19 and
o Adding one extra drug in the case of treatment failure. 15,19
Client-Related Factors
Client adherence is most often a problem when:
 The client is homeless, has a substance abuse problem, or is unemployed.
15,19 A family member has been unsuccessfully treated previously. 15,19
 Access to health care is difficult. 15,19
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2.7. RISK FACTORS FOR MDR-TB
The WHO has identified elements in the patient’s history that suggest an increased
risk for drug resistance as listed below.14 This study will not investigate all identified
risk factors.
List of Risk Factors for MDR-TB
Risk factor Comments
Failure of re-treatment
regimens and chronic TB
cases
These patients have the highest MDR-TB rates of any
other group, often greater than 80%.
Exposure to a known MDR-
TB case
Most studies have shown close contacts of MDR-TB
patients to have very high rates of MDR-TB.
Failure of first-time short
course chemotherapy
Failures for short course chemotherapy are patients who,
while on treatment, are sputum smear positive at 5
months or later during the course of treatment.
Relapse and return after
default
Erratic drug intake or early relapse may point to possible
MDR-TB.  Relapses within the first six months post-
treatment may have similar MDR-TB rates as failures.
History of using poor or
unknown quality TB drugs
The percentage of MDR-TB caused by use of poor
quality drugs is unknown but considered significant.
History of other medications
that interfere with TB drug
absorption
Antacids containing aluminium or magnesium selectively
compete with TB drugs, particularly with isoniazid and
fluoroquinolones.
Use of drugs that alter the
metabolism of TB drugs,
resulting in reduced serum
levels
Antifungal agents in the azoles family interfere with each
other; rifampicin will lower azole levels.  In addition,




These are usually non-DOTS programs or DOTS
programs with poor patient adherence or drug




Mal-absorption may result in selective low serum drug
levels and may occur in either HIV uninfected or HIV
infected patients.
HIV Numerous MDR-TB outbreaks have been documented in
HIV positive individuals, and XDR-TB outbreaks in HIV
positive individuals have been documented in South
Africa.
Source: World Health Organization. Guidelines for the Programmatic Management
of drug-resistant Tuberculosis (WHO/HTM/TB/2005.361), World Health
Organization: Geneva, Switzerland, 2006
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2.8. RISK FACTORS FOR MDR-TB UNDER INVESTIGATION
DEMOGRAPHIC CHARACTERISTICS
Age and sex
Data on drug resistance stratified by age and sex were reported by 42 settings in 36
countries from all World Health Organization Regions.  MDR-TB among combined
cases was found to be associated with the male sex and younger age groups (25 to
44 years old) in most of the WHO regions. 21
In a survey with 10 374 TB patients from 11 countries, patients aged 35 to 44 years
(OR 4.6; 95% CI: 1.1 to 18.9; p = 0.03) and 55 to 64 years (OR 4.4; 95% CI: 1.1 to
18.4; p = 0.04) were more likely to have MDR-TB.6 There were no significant
differences between males and females (OR 0.9; 95% CI: 0.7 to 1.1; p = 0.43). 6  A
study in Taiwan (n = 611) found that the overall proportion of drug resistance was
significantly higher in those aged less than 25years (79%; p=0.031) compared to
those aged 25 to 45 years (61%) and greater than 65 years (55.2%).27There was no
significant difference between males and females. 27
In South Africa, the National Survey of Tuberculosis Drug Resistance found that for
both new and re-treatment patients, there was no significant association between
MDR-TB and sex (OR 0.8; 95% CI; 0.6 to 1.1; p = 0.19) or age (p = 0.4). 25 A study
in Durban also found that there was no significant association between MDR-TB and
sex (OR 1.1; p = 0.2) or age (p = 0.6). 26
Race
In the United Kingdom, special risk groups for MDR-TB included being of Black
African, Indian, Pakistani, Bangladeshi or Chinese ethnicity. 28 In Durban, South
Africa it was found that there was no racial difference in prevalence between MDR-
TB and drug susceptible TB. 26 The South African national survey of tuberculosis
drug resistance did not investigate racial differences.25
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Geographical Location
There are wide variations in the proportions of TB drug resistance within all WHO
regions and all regions have reported outliers. 21 In South Africa, at a hospital in
Tugela Ferry, 41% of 544 culture positive TB patients were found to have MDR-TB
(n = 1539). 30
A study in Lucknow, India (n = 1162), found that only two isolates came from
patients who were residents of the same geographical locality. 7 The study was
unable to establish any geographical connection with MDR-TB.
REFERRAL TYPE
The literature is limited with regard to MDR-TB in different levels of care, and the
private or public sectors.  A study in Lucknow, India (n = 1162) found that the
prevalence of MDR-TB at tertiary level healthcare (27%) and secondary level
healthcare (20%) were significantly higher than at primary level healthcare (7.2%). A
study in Brazil found that statistically significant differences were found in the group
with drug resistance compared to the group with no resistance with respect to prior
hospitalization (51% versus 14%; p<0.001). 32
The South African National Survey of Tuberculosis Drug Resistance also found that
previous hospitalization was a significant determinant of drug resistance, both for
any drug resistance (OR 2.0; 95% CI: 1.3 to 3.1; p = 0.002) and for MDR-TB (OR
2.8; 95% CI: 1.6 to 4.9; p = 0.001). 25
In South Africa, TB treatment is available in the private sector but published
literature on MDR-TB in the private sector could not be found.
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PREVIOUS TB TREATMENT OUTCOMES
A history of previous TB treatment has been demonstrated to be the single most
important predictor of MDR-TB. 26 Those patients with a previous history of receiving
anti-tuberculosis therapy are more likely to have MDR-TB than those patients who
had no history of receiving anti-tuberculosis therapy (OR=4.4; CI: 3.2 to 5.9) (p <
0.05). 26
A study in Thailand (n = 1590) found that the prevalence of MDR-TB among all
patients was 10%, and the prevalence of MDR-TB among patients with a history of
previous TB treatment was 34%.31 The prevalence of MDR-TB was 75% in the
group, treatment after failure.  In the group of patients who had relapsed, the
prevalence of MDR-TB was 78%.31
In Brazil, a study where primary resistance was 7.0% and acquired resistance was
43%, found that there was a statistically significant association between history of
previous TB treatment and drug resistant TB (76%; p < 0.001). 32 The study also
found that having previously defaulted anti -TB treatment was strongly associated
with drug resistance (OR 7.2; 95% CI: 3.3 to 15.9; p < 0.001). 32
The South African National survey of Tuberculosis Drug Resistance investigated
MDR-TB among the four conventional previous TB treatment outcome categories,
namely: cured, treatment completion, treatment default and treatment failure.
Treatment failure was strongly associated with increased risk for MDR-TB (OR 13.3;
95% CI: 4.9 to 36.0; p < 0.001). 25 Patients who had previously defaulted from
treatment were also at higher risk for MDR-TB (OR 3.3; 95% CI: 1.3 to 8.1). Drug
resistance was twice as high when the previous TB outcome was defined as
‘treatment completed’ versus bacteriologically proven ‘cure’ (OR 2.1; 95% CI: 1.3 to
3.4; p < 0.001). 25
In a study on drug resistant tuberculosis among South African gold miners it was
found that previous treatment outcome was significantly associated with acquired
drug resistance in patients with re-treatment TB (p = 0.01)33. Patients who had
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previously failed primary TB treatment had a significantly higher risk of MDR-TB
(OR18.7; 95% CI: 1.76 to 475) compared to those who had completed TB treatment
(OR 2.2; 95% CI: 0.3 to 0.5). 33
The survey of tuberculosis drug resistance in KwaZulu-Natal analyzed drug
resistance among the different categories of re-treatment cases. Drug resistance
was detected in 25.9% of cases with a previously unsuccessful treatment outcome
(failure or interrupted), compared to 14.9% of patients with a successful treatment
outcome (cured or treatment completed). These differences were not statistically
significant (p = 0.07), but indicated that patients who fail or interrupt treatment are at
a higher risk for drug resistance. 35
PREVIOUS TB TREATMENT DURATION
A study involving 11 countries found that as the total duration of prior anti-
tuberculosis treatment increased, so did the likelihood of having MDR-TB (p <
0.001). 6 When compared with individuals without prior anti-tuberculosis treatment,
the study found that having received TB drugs for an overall period of time totaling 6
to 11 months (OR 7.6; 95% CI: 2.6 to 22.4; p < 0.001) or 12 months or greater (OR
13.7; 95% CI: 4.5 to 41.6; p < 0.001) was associated with MDR-TB. 6
A study in the Philippines found that there was an increased risk of acquiring
resistance with longer but incomplete anti-tuberculosis treatment. 37 The effect of
duration of previous anti-tuberculosis treatment on the resistance pattern showed
increasing odds of developing MDR-TB if treatment was taken for longer than 3
months but less than 6 months (OR = 4.6; p < 0.001). 37
The South African National Survey of Tuberculosis Drug Resistance found that the
duration of previous treatment was not significantly associated with drug resistance,
neither when testing for trend (1 month increase in treatment duration) nor when
treatment duration was dichotomized (less than 2 months versus 2 months or
longer), although trend analysis suggested a higher risk for any resistance with
prolonged treatment duration (OR 1.2; 95% CI: 1.0 to 1.5; p = 0.05). 25
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HIV and MDR-TB
The association between HIV and drug resistance is complex. “HIV co-infection is
not believed to increase the rate at which spontaneous resistance conferring
mutations occur”. 43 HIV co-infection might increase selection for spontaneous
mutations due to diminished adherence because of increased pill burden or toxic
effects, and sub-therapeutic concentrations of TB drugs because of malabsorption or
drug interactions. 43 Patients with HIV are more likely to progress to active disease
than HIV uninfected patients. HIV infection itself does not cause an increase in the
rate of drug resistant mutations but can increase the number of individuals who
select for drug resistance, or manifest active disease from resistant organisms
thereby accelerating the spread of drug resistant disease. 43
TB is the most common opportunistic infection and cause of death among HIV
infected patients in resource limited settings. 42 HIV infected patients are vulnerable
to primary disease following infection with TB and therefore at high risk of illness and
mortality when exposed to drug resistant TB strains. 42 HIV infected patients on
therapy still have a more than 5 fold increased risk of developing TB compared to
individuals without HIV infection.42
A systematic review of 32 studies assessing HIV infection as a risk factor for MDR-
TB was unable to demonstrate an overall association between HIV prevalence and
MDR-TB (prevalence ratio r = 0.209).5 The pooled prevalence ratio for acquired
MDR-TB and HIV was 1.17 (95% CI: 0.86 to 1.6; p = 0.19), and the pooled
prevalence ratio for primary MDR-TB and HIV was 2.72 (95% CI: 2.03 to 3.66; p =
0.36). 5 The results did suggest that HIV infection is associated with primary MDR-
TB. 5
A study in Northern Thailand found an association between HIV infection and
primary MDR-TB (OR 2.0; 95% CI: 1.1 to 3.5), but not acquired MDR-TB (OR 1.4;
95% CI: 0.7 to 2.9).31 A small study in India (n = 70), observed similar rates of MDR-
TB in HIV co-infected (10%) and HIV uninfected patients (2.5%).5
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Three studies in South Africa also found no association between HIV infection and
MDR-TB. In a retrospective study in Durban, 2.4% of 42 HIV co-infected and 11% of
HIV uninfected patients had MDR-TB.5 A prospective study of hospitalized TB
patients in Cape Town found a MDR-TB prevalence of 3.2% in 93 HIV co-infected
patients, compared to 2.6% in 115 HIV uninfected patients.5 In a study on gold
miners, the MDR-TB rate was 5.3% among 207 HIV co-infected and 6.5% among
215 HIV uninfected miners. 5 A study at a hospital in Tugela Ferry found that HIV
was a risk factor for XDR-TB (OR 8.2; CI: 1.3 – 52.6), but not for MDR-TB. 40
Contrary to the above findings the South African National Survey of Tuberculosis
Drug Resistance found that HIV infected patients tended to have a higher risk for
MDR-TB (OR 1.3; 95% CI: 1.0 to 1.7; p = 0.05). 25 The survey for KwaZulu-Natal
however, found that the association between HIV and MDR-TB was non-significant
(p = 0.18). 35
LENGTH OF TIME FROM TB DIAGNOSIS TO MDR-TB DIAGNOSIS
A study in South Africa enrolled patients who developed MDR-TB after being
diagnosed and treated for an initial infection with drug susceptible TB. The study
found that the median number of days between the collection of initial sputum (drug
susceptible) and second sputum (drug resistant) was 154 days (range: 68 to 321
days). 38 The study did not report on any association between the time from
collection of initial sputum to collection of second sputum, and MDR-TB. 38 At the
time of submission of this dissertation there were no other published studies found
investigation the length of time from TB diagnosis to MDR-TB diagnosis.
2.9. GAPS IN THE LITERATURE
The review of the current literature did not find any published studies investigating
the following:
 The association between MDR-TB and employment status;
 Duration of previous TB treatment interruption;
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 Length of time from previous episode of TB to current diagnosis of MDR-TB;
and
 Average length of time from MDR-TB diagnosis to MDR-TB treatment
commencement.
2.9. CHAPTER SUMMARY
Anti-tuberculosis drugs are effective for the treatment of TB, however, if they are
inappropriately used they can also lead to the selection of resistant mutants for
which the same drugs then become ineffective.20
The variability in the prevalence of MDR-TB between and within countries, and the
changes in MDR-TB prevalence over time, highlights the need for monitoring MDR-
TB prevalence at facilities were a large numbers of TB patients are managed. The
literature review has shown that various risk factors have been identified and
investigated, but not all risk factors have been found to be significantly associated
with MDR-TB, and there have been differences in association across studies. There
has been general consensus that the risk factors most frequently associated with
MDR-TB are previous TB treatment, previous TB treatment failure and previous TB
treatment default. This study will test the associations with the risk factors discussed
and MDR-TB at the Prince Cyril Zulu Communicable Disease Centre. The study will
also attempt to investigate aspects related to MDR-TB which have been identified as
gaps in the literature.
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CHAPTER 3. RESEARCH METHODS
3.1. INTRODUCTION
In this chapter, a comprehensive description of the research methods used in this
research project is presented. The design that was most appropriate to achieve the
objectives was used. The study population that was identified and the sampling
strategy that was used are described in detail. The data management and statistical
methods that were employed are also presented.
3.2. TYPE OF RESEARCH
This research project was categorized as health systems research.
3.3. STUDY DESIGN
An observational analytic nested case-control study design was used.
3.4. STUDY POPULATION
All patients who were diagnosed with pulmonary TB4, and who had a sputum
culture5 performed, at the Prince Cyril Zulu Communicable Disease Centre between
4 The South African National Tuberculosis Control Programme definition of pulmonary TB was used:
- If there are at least 2 sputum smears positive for acid fast bacilli, or
- 1 sputum smear positive for acid fast bacilli and chest X-ray abnormalities consistent with
active TB, or
- Sputum culture positive for TB, or
- Chest X-ray abnormalities that are consistent with active TB although 2 sputum smears
are negative for acid fast bacilli
5 Sputum is obtained from all TB suspects at the Prince Cyril Zulu Communicable Disease Centre.
Microscopy for acid fast bacilli is done at the Prince Cyril Zulu Communicable Disease Centre. If a
culture is requested then the sputum is transported to Inkosi Albert Luthuli hospital TB culture
laboratory where sputum culture and drug susceptibility testing is done. The Inkosi Albert Luthuli
Laboratory uses the modified proportion method for susceptibility testing for slow growing bacteria,
which is considered the gold standard, and is performed on 7H11 agar. Dilutions of inoculums are
seeded on both control and drug containing media so that countable colonies are obtained on at least
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2001 and 2007 constituted the study cohort and formed the denominator for the
calculation of prevalence which was the measure of disease occurrence used.
3.5. STUDY SITE
The study site was the Prince Cyril Zulu Communicable Disease Centre, located in
the city of Durban, KwaZulu-Natal, South Africa.
The Prince Cyril Zulu Communicable Disease Centre provides outpatient services
which include investigation, diagnosis and management of patients with TB, and
sexually transmitted infections. Voluntary counseling and testing for HIV (VCT)
services are also provided. The centre had an average of 3 to 5 doctors and 4 to 6
professional nurses during the study period.
 All self referred patients are screened by primary healthcare trained professional
nurses. Patients with symptoms of TB have 2 sputum smears done on 2 consecutive
days, one of which is an early morning sputum. The turnaround time for sputum
smear results at this facility has remained between 2 to 4 hours. Patients who have
2 positive smears are commenced on TB treatment.
A Chest X-ray is done for the following patients who have symptoms of TB and:-
 1 positive smear and 1 negative smear
 2 negative smears
 Chest pain
 Signs of respiratory distress.
 All patients referred from primary health clinics, hospitals or the private sector
one of the control media. The numbers of CFU that grow on a drug medium is then compared with
the number on the control media. From this the proportion of acid fast bacilli resistant to a given drug
can be calculated. The Inkosi Albert Luthuli Laboratory defines resistance as 1% or more growth
against critical drug concentration: 0.2ug/ml for isoniazid, 49ug/ml for rifampicin, 5ug/ml for
streptomycin and 2ug/ml for ethambutol.
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Sputum culture is performed for the following patients:-
 New patients who are symptomatic but sputum smear negative;
 New patients who are sputum smear positive with extensive changes on
chest  X-Ray;
 New patients who do not have radiological improvement after 2 months of
anti-TB treatment;
 New patients who remain sputum smear positive after 2 months of anti-TB -
treatment; and




The inclusion criteria were:
 All patients diagnosed with pulmonary TB who had a sputum specimen taken
for culture at the time of TB diagnosis
 Patients older than 8 years6 of age; and
 All cases of MDR-TB7.
Exclusion criteria
The exclusion criteria were:
 Patients who had extra-pulmonary TB; and
 Patients who had pulmonary TB but who did not have a sputum culture
performed.
6 Children under 8 years are unable to produce an adequate sputum specimen to confirm diagnosis of
MDR-TB
7 Cases of XDR-TB were included as MDR-TB cases because they adhere to the definition criteria of




The cases in this study were all MDR-TB cases diagnosed on sputum culture
between 2001 and 2007
Controls
The controls were drug susceptible TB cases which had a sputum culture done at
diagnosis, and were diagnosed in the same month as the MDR-TB case
Sampling process
If a patient was diagnosed with MDR-TB more than once during the period 2001 to
2007 each event would be counted separately and included in the analysis. The
inclusion criteria were all cases of MDR-TB. The XDR-TB cases were included as
MDR-TB cases. A separate analysis of XDR-TB was not an objective of this study.
One control was randomly selected for each case. Systematic random sampling was
done to select the controls. Each 100th pulmonary TB case after the MDR TB case
was selected. If the selected pulmonary TB patient did not satisfy the inclusion
criteria then the next 100th pulmonary TB case was selected as a control. The
selection from the electronic database was done manually. The controls were only
matched to cases with regard to the time of diagnosis. The controls had to be
diagnosed in the same month as the MDR-TB case. The controls were not matched
for age and sex because the investigator wanted to analyze for these demographic
characteristics. A similar case control study conducted at a hospital in Tugela Ferry,
South Africa used the same ratio of 1: 1 for selection of controls and controls were
not matched. 40
If a TB case was diagnosed more than once with TB during the study period, the
case would have been included more than once in the sample population. The
electronic database was automatically updated when a patient was diagnosed with
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TB. Therefore, although rare, the possibility did exist for a TB patient to be randomly
selected more than once as a control.
Subgroup
A subgroup of patients who had a history of previous TB treatment was selected
from the sample population.
The cases in the subgroup were MDR-TB cases which had a history of previous TB
treatment.
The controls in the subgroup were TB cases which had a history of previous TB
treatment.
3.8. DATA SOURCES
The Prince Cyril Zulu Communicable Disease Centre has had an electronic
database8 on which data for all patients since 2001 has been recorded. The cohort
of patients from which cases and controls were extracted were from this database.
Variables
The variables that were measured in this study were divided into independent and
dependent variables.
8 The database comprises of specific data elements which include patient demographic
characteristics ( age, sex, location, occupation), previous TB treatment outcomes, current symptoms,
sputum smear results, sputum culture results, chest X-rays, current TB case category (new or re-
treatment), site of TB, TB treatment given (dose, duration, quantity), type of DOTS, treatment
commencement dates, treatment completion dates, TB treatment outcome (cured, treatment
completed, died, treatment failure, defaulted, transferred out, moved out), HIV status.
The database also includes medical notes of every clinical consultation with the patient, which
documents clinical information including chest X-ray findings, duration of treatment interruption, side
effects of TB treatment, other medical conditions and any other relevant medical information. Patients
who return to the Prince Cyril Zulu Communicable Disease Centre for subsequent episodes of TB are
linked to their previous TB records through their patient identification numbers by limited, password
protected access to patient names and dates of birth, to enable continued follow-up of patients.
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 Independent variables
The independent variables measured included the following:
 Age
When data was collected, age was a continuous variable. Age was discretised
into categories (< 25 years; 25 – 45 years; 46 – 65 years; > 65 years).  Age was
changed to a categorical variable for analysis.
 Sex
Sex was defined as male or female. Sex was a categorical variable
 Race
Race was defined as African, Indian, Coloured or White. If data was missing for
race the category unknown was used. Race was a categorical variable.
 Geographical area
Geographical area was defined as North, South, West or Out of eThekwini.
Geographical area was a categorical variable.
 Employment status
Employment status was defined as being employed, unemployed, a scholar /
student or a pensioner. If data was missing for employment status then the
category unknown was used. Employment status was a categorical variable. The
database has specific data elements related to employment which included
whether employed (yes or no) and if employed what occupation.
 Previous TB treatment
The categories were defined as either yes, (there was a history was previous TB
treatment or no (there was no history or previous TB treatment).  Previous TB
treatment was a categorical variable
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 Duration of previous TB treatment
When data was collected, duration of previous TB treatment was a continuous
variable. Duration of previous TB treatment was discretised into categories (< 24
weeks; 24 – 32 weeks; > 32 weeks). Duration of previous TB treatment was
changed to a categorical variable for analysis.
 Previous TB treatment outcome
Previous TB treatment outcome was defined as previous TB cured; previous TB
treatment failure; previous TB treatment completed or previous TB treatment
defaulted. If data was missing for the previous TB treatment outcome then the
category unknown was used. Previous TB treatment outcome was a categorical
variable.
 Duration of previous TB treatment interruption
TB treatment interruption was defined as a patient whose treatment was
interrupted for more than two consecutive months before the end of the treatment
period. 15 When data was collected, duration of previous TB treatment interruption
was a continuous variable. Duration of previous TB treatment interruption was
discretised into categories (8 - 16 weeks; 16 – 24 weeks; > 24 weeks). Duration
of previous TB treatment interruption was changed to a categorical variable for
analysis.
 HIV status
HIV status was defined as HIV infected or HIV uninfected. If data was missing for
HIV status then the term unknown was used. HIV status was a categorical
variable.
 Referral Type
Referral type was defined as referral from a primary health clinic, a public
hospital, the private sector or a self referral. If data was missing for the referral
type then the term unknown was used. Referral type was a categorical variable.
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The database has specific data elements related to referral. The database has a
data element: referred (yes or no) and a second data element where one of the
following categories has to be ticked: Primary health clinic, hospital, private.
 Timelines.
The study design enabled follow-up of MDR-TB cases from previous TB to
current TB diagnosis and MDR-TB diagnosis. The study design also allowed for
follow-up of the MDR-TB cases until MDR-TB treatment commencement or death
before MDR-TB treatment commencement.
There were 4 different timelines defined:
- Time from previous TB diagnosis to MDR-TB diagnosis.
- Time from current TB diagnosis to MDR-TB diagnosis
- Time from MDR-TB diagnosis to MDR-TB treatment
- Time from current TB diagnosis to death for MDR-TB cases
Timelines were continuous variables.
The date of registration of the TB case was taken as the date of diagnosis of the
TB case. The database has a data element where this date has to be entered for
every TB case.
Similarly there is a data element where the date of registration of an MDR-TB
case is entered. This corresponds to the date the MDR-TB culture results were
received.
The date that the MDR-TB treatment was commenced is the same as the date
that the patient was admitted to the MDR-TB referral hospital where MDR-TB
treatment is commenced. MDR-TB patients visit the Prince Cyril Zulu
Communicable Disease Centre on the day of their admission to the MDR-TB
referral hospital because they are transported in hospital transport. An entry is
made on the database indicating the date of admission.
Death among MDR-TB patients, refers to death before MDR-TB treatment is
commenced. The South African National Tuberculosis guideline definition of died
was used, “client who dies for any reason during the course of TB treatment”.
Every MDR-TB patient is followed up on a monthly basis while they are awaiting
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a bed for admission to hospital. If the patient does not return for their follow-up
visit then the patient is contacted or traced. If death is reported an entry is made
in the database where there is a data element on death.
 Dependent variable
The dependent variable measured was MDR-TB.
3.9. RELIABILITY
The reliability of the data was ensured by the use of the following procedures:
 All patient data recorded in the database was initially obtained by clerks at the
point of entry to the facility. Data was then rechecked and corrected by the
doctors during the patient’s medical consultation. If the doctors did not check
that all the relevant information that was captured was correct and there were
errors or missing data then the doctors would not have been able to move to
the next page of the electronic database. Missing information, incorrect
information entered that does not correlate would prevent the doctors from
completing the patients TB registration, TB notification and prescription, which
are all automatically generated provided all the information has been correctly
entered into the database. This would cause delays, so to ensure efficiency
the doctors routinely cross check the information captured on each electronic
page before moving to the next page to ensure that delays do not occur.
 The database utilized the computer programme Access (“Datacare”) which
had automatic checks and re-checks to ensure that data had been correctly
entered.
3.10. VALIDITY
The validity of the study was established through the utilization of an appropriate
study design and through the random selection of controls.
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3.11. REDUCTION OF BIAS
Different forms of bias were reduced in the following ways:
 Information bias was reduced by obtaining information on risk factors before
the cases were identified. The information was obtained at the patient’s first
visit to the Prince Cyril Zulu Communicable Disease Centre, this was before
the diagnosis of MDR-TB.
 Sampling bias was reduced by selecting all cases of MDR-TB and through
the random selection of controls.
3.12. DATA COLLECTION AND HANDLING
The following processes outline how data was collected and handled:
 Data was obtained from the database by the researcher.
 Data was cleaned and verified by cross checking data elements in the
database with patient’s medical notes9 and laboratory results10 in the
database.  If data was missing in the database the investigator informed the
Prince Cyril Zulu Communicable Disease Centre Information Technology
Support Specialist (Mrs. Sally Chetty), who then accessed the hard copies of
9 Patient’s medical notes are recorded in the database under patient identification numbers. Patient’s
medical notes in the database are not linked to patient names or South African Identity Numbers. In
addition to the database, a hard copy of patient’s medical notes is kept at the Prince Cyril Zulu
Communicable Disease Centre. These hard copies contain the patient names in addition to the
patient identification numbers.
10 Laboratory results are recorded in the database under patient identification numbers. Patient’s
laboratory results which appear in the database are not linked to patient names or South African
Identity Numbers. Hard copies of laboratory results, which have patient names and Prince Cyril Zulu
Communicable Disease Centre patient identification numbers, are received from the TB culture
laboratory (Inkosi Albert Luthuli Laboratory) by the Prince Cyril Zulu Communicable Disease Centre
laboratory staff. The full culture result is entered into the database by the Prince Cyril Zulu
Communicable Disease Centre laboratory staff under the patient identification numbers.
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patient’s medical notes and laboratory results and populated the database
with the missing data.
 Confidentiality was maintained at all times. Data was not linked to individual
patients. Access to match patient names and identification numbers was
password protected and limited to 3 users at the Prince Cyril Zulu
Communicable Disease Centre. The investigator was not given access to any
data that contained patient names. The researcher did not disclose the
password to the database to anyone and therefore maintained confidentiality.
 All datasheets and flash discs that contained information from the database
were stored in a lock-up cabinet to avoid third persons unrelated to the study
gaining access to said materials. At the end of the study, all datasheets
containing information from the database were shredded and destroyed by
the investigator. Electronic copies of the datasheets were deleted.
 Individual patient data was not shared with the statistician, only summarized
data was shared.
 Analysis of the data was done by the researcher under the direction of a
statistician (Dr Gaetan Kabera).
 The investigator used the information obtained from the database solely for
the purpose of the above study.
3.13. STATISTICAL METHODS
The statistical methods used were both descriptive and analytic. These methods are
described below:
Descriptive
 Data was captured using the statistical package STATA, IC version 11. The
distribution of the data was not uniformly distributed and therefore the median
and the inter-quartile range were calculated.




 Inferential statistics namely, Chi-square test, logistic regression, Wilcoxon
rank sum test, and Kaplan-Meier survival analysis were used to reach
conclusions about how the data related to the research objectives.
 Data analysis was done using the statistical package STATA, IC version 11
and 17.
 Analysis of bivariate data was done as follows:
o Data was grouped in the form of tables and cross tabulation was done
to examine if the variables were significantly associated with the case
or control status using Pearsons chi square tests for categorical
variables.
o The measure of association was also statistically tested using logistic
regression and reporting odds ratios for categorical data.
o A 5% level of significance was used.
o The measure of association between a binary response variable and a
continuous variable was assessed using binary logistic regression
model, odds ratios with an associated 95% confidence interval and p-
value were reported.
o For comparing continuous data across categories of a binary factor the
Wilcoxon rank sum test was used.
 Multivariate logistic regression analysis was performed to assess the
independent effects of each risk factor while controlling for confounding
factors.
 Kaplan-Meier survival analysis was used to determine time to event between
independent groups for continuous variables. Kaplan-Meier was used
because survival function and survival probability had to be investigated. The
log rank test was not used because the survival analysis was only done for
the cases. There were no controls for these variables so a comparison of 2
curves could not be made.
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 Subgroup analysis was done using Chi square test, logistic regression and
Wilcoxon rank sum test to assess measures of association for categorical
data. Odds ratios with a 95% confidence interval were reported on.
Confounders
Age, sex, HIV infection and employment status were identified as possible
confounders
Associations measured






Previous TB treatment MDR-TB
Duration of previous treatment MDR-TB
Previous TB cured MDR-TB
Previous TB treatment failure MDR-TB
Previous TB treatment completed MDR-TB
Previous TB treatment defaulted MDR-TB
Duration of previous treatment interruption MDR-TB
HIV status MDR-TB
Referral Type MDR-TB
3.14. LIMITATIONS OF THE RESEARCH METHOD
The limitations of the research method used were:
 The study was retrospective and therefore limited to the data that was
available in the existing database.
 The study was limited to those patients who had a sputum culture performed
at the Prince Cyril Zulu Communicable Disease Centre.
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These limitations did not affect the quality of the data. Although retrospective, the
data for most variables was complete. For most demographic characteristics data
was missing for less than 5 cases or controls. The variable most affected by
unknown data was HIV status, but this was due to patients not having tested and not
due to missing data. An adequate number of patients had sputum culture performed,
10 205 and this did not affect the quality of the data.
3.15. CHAPTER SUMMARY
The details of the research process were described in this chapter. The contents of
this chapter showed that scientifically acceptable research methods were used to
investigate the MDR-TB prevalence and associated risk factors for MDR-TB at the




The results of the analysis of the data are presented in his chapter. The results are
presented in tabular and graphical form according to MDR-TB prevalence,
demographic characteristics, previous TB treatment (subgroup), TB and MDR-TB
timelines.
4.2. PREVALENCE OF MDR-TB
During the period from 2001 to 2007 the Prince Cyril Zulu Communicable Disease
Centre performed 10 205 sputum cultures from pulmonary TB cases. Multi-drug
resistant tuberculosis was found in 445 of these TB cases. The prevalence of MDR-
TB for the period 2001 to 2007 was 4.4% (n = 10 205); 4.3% (n = 3308) MDR-TB
cases among new TB cases and 4.4% (n = 6897) MDR-TB cases among previously
treated TB cases (Table 3). All MDR-TB cases had a single episode of MDR-TB
diagnosed at the Prince Cyril Zulu Communicable Disease Centre between 2001
and 2007. Each MDR-TB case was counted once.  (For total MDR-TB prevalence:
numerator = total number of MDR-TB cases and denominator = total TB cases with
sputum culture. For MDR-TB prevalence among new TB cases: numerator = MDR-
TB cases among new TB cases, and denominator = total number of new TB cases
with sputum culture. For MDR-TB prevalence among previously treated TB cases:
numerator = MDR-TB cases among previously treated TB cases and denominator =
total number of previously TB cases with sputum culture.)
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Table 3: Prevalence of MDR-TB at the Prince Cyril Zulu Communicable Disease Centre from 2001 to 2007 (n = 10 205)
All cases New TB cases Previously treated TB cases
Year Cultures
MDR-




of OR (CI) Cultures
MDR-
TB Prevalence of OR(CI)
cases Prevalence cases MDR-TB cases MDR-TB
2001 1116 17 1.5 346 8 2.3 1(Ref) 770 9 1.2 1 (Ref)
2002 1305 41 3.1 418 12 2.9 1.2 (0.5 - 3.9) 887 29 3.3 2.9 (1.3 - 6.1)
2003 1510 74 4.9 519 16 3.1 1.3 (0.6 - 3.2) 991 58 5.8 5.3 (2.6 - 10.7)
2004 1574 67 4.2 488 15 3.1 1.3 (0.6 - 3.2) 1086 52 4.8 4.3 (2.1 - 8.7)
2005 1433 63 4.3 459 10 2.2 0.9 (0.4 - 2.4) 974 53 5.4 4.9 (2.4 - 9.9)
2006 1586 65 4.1 523 17 3.2 1.4 (0.6 - 3.3) 1063 48 4.5 4.0 (2.0 - 8.2)
2007 1681 118 7.0 555 65 11.7 5.6 (2.7 -11.8) 1126 53 4.7 4.2 (2.0 - 8.5)
10 205 445 4.4 3308 143 4.3 6897 302 4.4
OR = Odds ratio


























Prevalence of MDR-TB among New TB cases    MDR-TB Prevalence
Prevalence of MDR-TB among previously  treated TB cases
Figure 4: Prevalence of MDR-TB at the Prince Cyril Zulu Communicable
Disease Centre from 2001 to 2007
The prevalence of Multi-drug resistant tuberculosis at the Prince Cyril Zulu
Communicable Disease Centre was 1.5% (n = 1116) in 2001(Figure 4). The
prevalence of MDR-TB increased to 4.9% (n = 1510) in 2003 and remained stable at
around 4% for the next three years. There was an increase in the prevalence of
MDR-TB after 2006 with an MDR-TB prevalence of 7% (n = 1681) in 2007 (Figure
4).
There was an increase in the prevalence of MDR-TB among new cases from 3.2%
(n= 523) in 2006 to 11.7% (n = 555) in 2007 (Table 3). The increase in prevalence of
MDR-TB among new cases in 2007 relative to 2001 was significant (OR 5.6; 95%
CI: 2.7 to 11.8) (Table 3). The prevalence of MDR-TB among previously treated TB
cases was low, 1.2% (n = 770) in 2001 with an increase to 4.7% (n = 1126) in 2007
(Table 3).
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From 2002 to 2006 the prevalence of MDR-TB has had a trend of being higher
among previously treated TB cases when compared to new TB cases. This trend
changed in 2007 when the prevalence of MDR-TB cases was higher (11.7%) (n =
555) among new TB cases when compared to previously treated TB cases (4.7%) (n
= 1126) (Figure 4).
4.3. DEMOGRAPHIC CHARACTERISTICSS
During the period 2001 to 2007, the Prince Cyril Zulu Communicable disease Centre
had 445 culture confirmed cases of MDR-TB. The study sample population was
therefore 890 (Table 4), which comprised of 445 cases (MDR-TB cases) and 445
controls (drug susceptible TB cases).
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Table 4: Demographic characteristics of study sample population at the Prince Cyril
Zulu Communicable Disease Centre from 2001 to 2007. (n = 890)
Chi square test Logistic regression
Cases (%) Controls (%) P-value OR (95%CI) P- value
N (890) 445(50) 445(50)
Age 0.3
Median (IQR) 35 (29 - 43) 13 - 80
< 25 years 53(12) 67(15) 1 (Ref)
25 - 45 years 293(66) 287(65) 1.3 (0.9 - 1.9) 0.2
46 - 65 years 94(21) 86(19) 1.4 (0.9 - 2.2) 0.2
> 65 years 5(1) 5(1) 1.3 (0.4 - 4.6) 0.7
Sex 0.2
Male 260(58) 279(63) 1 (Ref)
Female 185(42) 166(37) 1.2 (0.9 - 1.6) 0.2
Race 0.4
African 406(91) 395(89) 1 (Ref)
Indian 22(5) 33(7) 0.6 (0.4 - 1.1) 0.1
Coloured 11(2.5) 12(3) 0.9 ( 0.4 - 2.0) 0.8
White 2(0.5) 0 _
Unknown 4(1) 5(1) _
Geographic Area 0.6
Out of eThekwini 5(1) 6(1.5) 1 (Ref )
North 130(29) 112(25) 1.3 (0.4 - 4.7) 0.6
South 289(65) 305(68.5) 1.1 (0.3 - 3.8) 0.8
West 21(5) 22(5) 1.1 (0.3 - 4.3) 0.8
Employment status 0.7
Employed 150(33) 155(35) 1 (Ref)
Unemployed 289(65) 283(63.6) 1.0 (0.8 - 1.4) 0.7
Scholar / student 3(1) 5(1) 0.6 (0.2- 2.6) 0.5
Pensioner 0 1(0.2) _
Unknown 3(1) 1(0.2) _
Referral Type 0.4
Primary Health
Clinic 29(6.5) 31(7) 1 (Ref)
Public Hospital 133(30) 152(34) 0.9 (0.5 - 1.6) 0.8
Private Sector 38(8.5) 42(9.5) 0.9 (0.5 - 1.9) 0.9
Self Referral 136(30) 134(30) 1.0 (0.6 - 1.9) 0.8
Unknown 109(25) 86(19.5) _
HIV Status
HIV Uninfected 9(2) 6(1) 0.9 1 ( Ref)
HIV Infected 92(21) 62(14) 1.0 (0.3 - 2.9) 0.9
Unknown 344(77) 377(85) _
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4.3.1. Age
The median age among the MDR-TB cases was 35 years with an inter-quartile
range of 29 to 43 years. The median age among the controls was 34 years with an
inter-quartile range of 29 to 42 years (Table 4). There was no significant difference in
age between the MDR-TB cases and controls (p = 0.3). Almost 80% (n = 445) of
cases with MDR-TB were less than 45 years old.
4.3.2. Sex
There was no significant difference in sex between the MDR-TB cases and the
controls (OR 1.2; 95% CI: 0.9 to 1.6; p = 0.2) (Table 4).
4.3.3. Race
There was no significant difference between the different race groups among the
MDR-TB cases and the controls, p = 0.4 (Table 4). The proportion of MDR-TB cases
was highest among the African race group, but this was not significant when
compared to the Indian race group (OR 0.6; 95% CI: 0.4 to 1.1; p = 0.1) or when
compared to the Coloured race group (OR 0.9; 95% CI: 0.4 to 2.0; p = 0.8)) (Table
4). Comparison with the White race group was not possible due to the small
numbers.
4.3.4. Geographical area
There was no significant difference between the different geographical areas among
the MDR-TB cases and the drug susceptible TB cases, p = 0.6 (Table 4). A high
proportion of MDR-TB cases, 65% (n = 445) and controls, 69% (n = 445) came from




A high proportion, 65.0% (n = 445) of MDR-TB cases and 63.5% (n = 445) of
controls where unemployed but there was no significant difference between being
employed and unemployed among the MDR-TB cases and the controls, (OR 1.0;
95% CI: 0.8 to 1.4; p = 0.7) (Table 4).
4.4. REFERRAL TYPE
Among the MDR-TB cases, the highest proportion of cases where referrals from
public hospitals, 30% (n = 445) and self referrals, 30% (n = 445). The private sector
contributed, 8.5% (n = 445) of the MDR-TB cases, this was higher than the referrals
from the primary health care clinics, 6.5% (n = 445) (Table 4).
There was no significant difference between the origin of referral namely: self
referral, private sector, public hospital and primary health care clinic among the
MDR-TB cases and the controls, p = 0.4 (Table 4).
The highest proportion of referrals came from public hospitals but this was not
significant (OR 0.9; 95% CI: 0.5 to 1.6; p = 0.8) (Table 4). Similarly self referrals
were not significant (OR 1.0; 95% CI: 0.6 to 1.9; p = 0.8) (Table 4).
4.5. HIV STATUS
There was no significant difference in HIV status between MDR-TB cases and
controls, (OR 0.1, 95% CI 0.3 to 2.9; p = 0.9) (Table 4). The HIV status of a large
proportion of cases, 75% (n = 445) and controls, 85% (n = 445) was unknown  Due
to the small number of cases with a known HIV status a breakdown of HIV status




The subgroup analysis found that 603 patients from the 890 patients in the sample
population had previous TB (Table 5). This was a high proportion, 67.8% (n = 603) of
previous TB treatment. The 603 patients with previous TB comprised of 302 cases (MDR-TB
cases) and 301 controls (drug susceptible TB cases). There was no significant difference in
previous TB treatment between the MDR-TB cases and the controls, p = 0.9 (OR 1; 95% CI:
0.7 to 1.3) (Table 5).
Table 5: Subgroup analysis of cases with previous TB at the Prince Cyril Zulu
Communicable Disease Centre from 2001 to 2007.











n = 445 n = 445





Treatment completed 97(32) 129(43) 1 (Ref)
Cured 84(28) 55(18) 2.0 (1.3 - 3.1) 0.001
Treatment failure 61(20) 42(14) 1.9 (1.2 - 3.1) 0.006
Treatment defaulted 60(20) 73(24) 1.1 (0.7 - 1.7) 0.7
Unknown 0 2(1) _ _
Duration of previous TB treatment 0.005
in weeks (n=603)
Median 28 28
Inter quartile range 28 - 34 24 - 28
< 24 weeks 59(20) 72(24) 1 (Ref)
24 - 32 weeks 160(53) 179(59) 1.1 (0.7 - 1.6) 0.7
> 32 weeks 83(27) 50(59) 2.0 (1.2 - 3.3) 0.005
Duration of previous TB
treatment interruption
in weeks (n=243) 0.3
Median 20 18
Inter quartile range 14 - 24 16 - 22
8 - 16 weeks 18(16) 16(12) 1 (Ref)
16 - 24 weeks 28(25) 41(32) 0.6 (0.3 - 1.4) 0.2
>24 week 67(59) 73(56) 1.2 (0.5 - 2.9) 0.7
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4.6.1. Previous TB treatment outcome
Previous TB treatment outcome between MDR-TB cases and controls was
significant, p = 0.004 (Table 5). A previous TB treatment outcome of treatment
failure was significantly associated with MDR-TB (OR 1.9; 95% CI: 1.2 to 3.1; p =
0.006) (Table 5). A previous TB treatment outcome of cure was significantly
associated with MDR-TB (OR 2.0; 95% CI: 1.3 to 3.1; p = 0.001), when compared to
treatment completed. A previous TB treatment outcome of treatment default among
MDR-TB cases and controls was not significant (OR 1.1; 95% CI: 0.7 to 1.7; p =
0.7), when compared to treatment completed. (Table 5)
4.6.2. Duration of previous TB treatment
The median duration of previous TB treatment among MDR-TB cases was 28
weeks, inter-quartile range from 28 to 34. The median duration of previous TB
treatment among the controls was 28 weeks, inter-quartile range from 24 to 28
(Table 5). There was significant difference in the duration of previous TB treatment
between the MDR-TB cases and the controls, p = 0.005 (Table 5). A duration of
previous TB treatment of greater than 32 weeks was significantly associated with
MDR-TB (OR 2.0; 95% CI: 1.2 to 3.3; p = 0.005) (Table 5). A duration of previous TB
treatment of 24 to 32 weeks was not significantly associated with MDR-TB (OR 1.1;
95% CI: 0.7 to 1.6; p = 0.07). (Table 5)
4.6.3. Duration of previous TB treatment interruption
The median duration of previous TB treatment interruption among the MDR-TB
cases (n = 113) was 20 weeks with an inter-quartile range from 14 to 24 weeks
(Table 5). The median duration of previous TB treatment interruption among the
controls (n = 130) was 18 weeks with an inter-quartile range from 16 to 22 weeks
(Table 5). There was no significant difference in the duration of previous TB
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treatment interruption between the MDR-TB cases and the controls (p = 0.3) (Table
5).
Table 6: Multiple regression models for MDR-TB patients with previous TB
treatment (n = 603)
Model 1: MDR-TB versus age group and duration of previous TB treatment (n = 603)
Odds Ratio 95% CI P-value
Age
< 25 years 1 (Ref)
25 - 45 years 1.7 (1.00 - 2.99) 0.05
> 46 years 2.0 ( 1.1 - 3.6) 0.03
Duration previous TB treatment
<24 weeks 1 (Ref)
24-32 weeks 1.1 ( 0.7 - 1.6) 0.81
>32 weeks 2.0 (1.2 - 3.2) 0.01
Model 2: MDR-TB versus age group and previous TB treatment outcome (n = 601)
Age
< 25 years 1 (Ref)
25 - 45 years 1.8 (1.0 - 3.2) 0.03
> 46 years 2.0 (1.1 - 3.7) 0.03
Previous TB treatment outcome
Treatment completed 1 (Ref)
Cured 1.9 (1.3 - 3.0) 0.003
Treatment failure 2.1 (1.3 - 3.4) 0.003
Treatment defaulted 1.1 (0.7 - 1.7) 0.58
4.7. MULTIVARIATE ANALYSIS
The multivariate analysis was done using logistic regression (Table 6). No significant
variables were found when the full dataset was used. When the analysis was
restricted to the subgroup of previously treated cases, 2 multiple logistic regression
models had significant findings. In the multiple regression models for previously
treated TB cases, age was found to be significantly associated with MDR-TB.
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In model 1: age group and duration of previous TB treatment were associated with
MDR-TB.  There was a significant association between the age group > 46 years
and MDR-TB (OR 2.0; 95 % CI: 1.1 to 3.6, p = 0.03).
In model 2: The age groups 25 – 45 years (OR 1.8; 95% CI: 1.0 to 3.2; (p = 0.03)
and the age group > 46 years (OR 2.0; 95% CI: 1.1 to 3.7; p = 0.03) were
significantly associated with MDR-TB. (Table 6)
Table 7: Timelines from TB diagnosis to MDR-TB diagnosis, treatment and
death at the Prince Cyril Zulu Communicable Disease Centre from 2001 to
2007.
N Median IQR
Time from previous TB to MDR-TB diagnosis (Days) 212 560 392 - 1092
Time from current TB diagnosis to MDR-TB diagnosis (Days) 445 98 77 - 140
Time from MDR-TB diagnosis to MDR-TB treatment (Days) 192 10 1 - 32
Time from current TB diagnosis to death for MDR-TB cases (Days) 27 87 29 - 159
4.8. MDR-TB TIMELINES
The data was not uniformly distributed therefore medians and the inter quartile range (IQR)
are reported (Table 7). All MDR-TB cases had a single episode of MDR-TB diagnosed at the
Prince Cyril Zulu Communicable Disease Centre between 2001 and 2007. All MDR-TB
cases were only counted once. If there were more than one previous episodes of TB, then
the time lines were calculated from the last previous episode of TB.
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Figure 5: Time from previous TB to MDR-TB diagnosis at the Prince Cyril Zulu
Communicable Disease Centre from 2001 to 2007 (n = 212)
4.8.1. Time from previous TB to MDR-TB diagnosis
The median time from previous TB to MDR-TB diagnosis was 560 days, inter
quartile range 392 to 1092 days (n = 212) (Table 7). With an increase in time beyond
2500 days after a previous episode of TB the probability of developing MDR-TB
decreased to less than 10% (Figure 5).
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Figure 6: Time from current TB diagnosis to MDR-TB diagnosis at the Prince
Cyril Zulu Communicable Disease Centre from 2001 to 2007 (n = 445)
4.8.2. Time from current TB diagnosis to MDR-TB diagnosis
The median time from current TB diagnosis to MDR-TB diagnosis was 98 days, inter
quartile range 77 to 140 days (n = 445) (Table 7).
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Figure 7: Time from MDR-TB diagnosis to MDR-TB treatment at the Prince
Cyril Zulu Communicable Disease Centre from 2001 to 2007 (n = 192)
4.8.3. Time from MDR-TB diagnosis to MDR-TB treatment
The median time from MDR-TB diagnosis to MDR-TB treatment was 10 days, inter
quartile range 1 to 32 days (n = 192) (Table 7).
58
Figure 8: Time from current TB diagnosis to death at the Prince Cyril Zulu
Communicable Disease Centre from 2001 to 2007 (n = 27)
4.8.4. Time from current TB diagnosis to death
The MDR-TB cases were followed up until MDR-TB treatment was commenced.
The results from this study that relate to death, refers to patients who died before
starting MDR-TB treatment. MDR-TB cases that died were included in the analysis.
The median time from current TB diagnosis to death for MDR-TB cases was 87
days, inter quartile range 29 to 159 (n = 27), (Table 7). The Kaplan-Meier curve
demonstrates that the probability of death decreases as length of from the current







Died before starting MDR-TB
treatment
Loss to follow up due to patient
moved or transferred to another
facility before MDR-TB diagnosis
Loss to follow-up due to patient
default from TB treatment before
MDR-TB diagnosis
Unknown
Figure 9: MDR-TB outcomes at the Prince Cyril Zulu Communicable Disease
Centre between 2001 and 2007 (n = 445)
4.9. MDR-TB FOLLOW-UP OUTCOMES
Analysis was done of the outcome of the 445 MDR-TB cases that were diagnosed at
the Prince Cyril Zulu Communicable Disease Centre between 2001 and 2007
(Figure 9). It was confirmed that 43% (n = 445) of MDR-TB cases had commenced
MDR-TB treatment at the MDR-TB referral hospital. A large proportion, 47% (n =
445) were lost to study follow-up. From the MDR-TB cases that were lost to follow-
up, 23% (n = 209) of the cases were lost to study follow-up because the patients
were moved or transferred to another facility and 24% (n = 209) of the cases were
lost to study follow-up because the patients defaulted from TB treatment before the
MDR-TB diagnosis was made (Figure 9). A concerning finding was that 7% (n = 445)
of MDR-TB cases died before they started MDR-TB treatment (Figure 9).
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4.10. CHAPTER SUMMARY
The important finding of this study was that the Prince Cyril Zulu Communicable
Disease Centre experienced an increase in the prevalence of MDR-TB in 2007
which was largely due to the increase in prevalence of MDR-TB among new TB
cases. The MDR-TB prevalence increased to 11.7% among new TB cases in 2007,
this increase in prevalence of MDR-TB among new TB cases was significant. The
study found that there was no significant association between age, sex, race,
geographic area, employment status, referral type, HIV status and MDR-TB. The
subgroup analysis of patients with previous TB found that there was a significant
association with a previous TB treatment outcome of treatment failure and MDR-TB.
A duration of previous TB treatment of greater than 32 weeks was also found to be
significantly associated with MDR-TB. Among patients with previous TB treatment,
age > 46 years was significantly associated with MDR-TB. The median time from TB
diagnosis to MDR-TB diagnosis was 98 days and from current TB diagnosis to
MDR-TB treatment 10 days. It was confirmed that 43% of MDR-TB cases
commenced MDR-TB treatment and 47% of MDR-TB cases were lost to study
follow-up. Seven percent of MDR-TB cases died before commencing MDR-TB
treatment. The median time from current TB diagnosis to death was 87 days. These




The results that were presented in the previous chapter are discussed in this
chapter.  The prevalence of MDR-TB at the Prince Cyril Zulu Communicable
Disease Centre is discussed in relation to the provincial, national and global
prevalence of MDR-TB.  Risk factors associated with MDR-TB are compared with
the results from other studies.  MDR-TB timelines and outcomes are discussed.
Possible explanations for some of the results are provided.
5.2. PREVALENCE OF MDR-TB
The prevalence of MDR-TB at the Prince Cyril Zulu Communicable Disease Centre
in 2001 (1.5%: 0.7% among new cases and 0.8% among previously treated TB
cases) was lower than the prevalence of MDR-TB in KwaZulu-Natal (2001: 1.7%
among new cases and 7.7% in previously treated TB cases). 35 The prevalence of
MDR-TB at Prince Cyril Zulu Communicable Disease Centre was also lower than the
national prevalence of MDR-TB in South Africa in 2002 (2.9%: 1.6% in new cases
and 6.6% in previously treated TB cases).25 For the period 2001 to 2002 the
prevalence of MDR-TB was also similar to the global picture where MDR-TB isolates
constituted 1 to 3% of global isolates. 7.
The increase in MDR-TB prevalence at the Prince Cyril Zulu Communicable Disease
Centre to 4.9% in 2003 may have been due to increased staff awareness following
the national drug resistance survey in 2002 which could have led to improved case
detection and reporting The number of sputum cultures done by the Prince Cyril Zulu
Communicable Disease Centre in 2003 increased by 15% compared to the number
of sputum cultures done in 2002 (Table 3). It has been reported in the United States,
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that with increased awareness and earlier diagnosis, mortality among HIV infected
MDR-TB cases improved from 100% to 50%.
The consistency of the prevalence of MDR-TB at the Prince Cyril Zulu
Communicable Disease Centre from 2003 to 2006, remaining around 4% was
probably due to the stability of the performance of the tuberculosis programme at the
facility.  The treatment success, treatment failures and treatment defaulters
remained consistent over this period (Figure 3).
The sudden increase in the prevalence of MDR-TB at the Prince Cyril Zulu
Communicable Disease Centre from 4.1% in 2006 to 7% in 2007 was an important
finding.  The importance of this finding is that is that most of this increase occurred
among new TB cases (Figure 4).  The increase in MDR-TB prevalence among new
cases to 11.7 % in 2007 was significant (OR 5.6; 95% CI 2.65 to 11.83) .This implies
that the risk of new TB patients developing MDR-TB was 5 times greater in 2007
compared to 2001. For South Africa the MDR-TB prevalence among new TB cases
was 1.8% in 2007.1 A MDR-TB prevalence of 11.7% among new TB cases is high.
There was no available data for the provinces for 2007.
A possible explanation for the increase in prevalence of MDR-TB among new TB
cases is increased awareness around drug resistance and therefore increased case
detection. The XDR-TB outbreak in Tugela Ferry occurred in 2005, but information
about the outbreak was released in 2006.  There was a large amount of media
coverage in 2006 of the XDR-TB outbreak in Tugela Ferry, 30 which may have
contributed to increased awareness and a higher index of suspicion for MDR-TB and
XDR-TB. If improved awareness and increased case detection was the explanation
for the increased prevalence of MDR-TB among new TB cases, there would have
been an increase in the number of sputum cultures done by the Prince Cyril Zulu
Communicable Disease Centre in 2007.  The results however show that there was
only a 6% (95) increase in the number of sputum cultures done from 2006 to 2007
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(Table 3), compared to the 11% (153) increase in the number of sputum cultures
done from 2005 to 2006.
“High defaulter rates for drug susceptible TB treatment, likely resulted in the creation
of large numbers of MDR-TB strains.” 41 The Prince Cyril Zulu Communicable
Disease Centre does have a high defaulter rate contributing to the development of
MDR-TB. The defaulter rate for 2001, 2006 and 2007 was 24.3%, 28.7% and 27.6%
respectively (figure 2). This does not explain the exponential rise in MDR-TB cases.
The most likely explanation for the increase in prevalence of MDR-TB among new
TB cases is that there was increased transmission of MDR-TB in 2007. The
transmission of drug resistant TB is the same as for drug susceptible strains,
transmission of TB occurs through droplet nuclei, aerosolized by patients with
infectious pulmonary TB and inhaled by another individual. 43 The Prince Cyril Zulu
Communicable Disease Centre is an outpatient facility, so confirmed MDR-TB
patients are sent home, back into the community while waiting for MDR-TB
treatment. The finding that patients with confirmed MDR-TB waited a median time of
98 days for diagnosis and an additional 10 days before  treatment commencement is
probably the biggest contributory factor (Table 7). This does not include the time
from the start of symptoms until attending the clinic. The Prince Cyril Zulu
Communicable Disease Centre does limit patients diagnosed with MDR-TB from
working, but no other restrictions are placed on patients while they are waiting for
MDR-TB treatment.  Patients are informed of basic infection control measures
(cough practices, natural ventilation) but masks are not issued to patients and
patients are not restricted from using public transport or attending community
gatherings. The Prince Cyril Zulu Communicable Disease Centre has adequate
infection control measures with regard to the structure of the building; waiting area
design and a negative pressure ventilation system to reduce transmission of TB
within the facility. Infection control measures at a facility level are well documented
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but there is limited literature on infection control in a household and community
setting.41
A MDR-TB ‘hot spot’ is defined by the World Health Organization as a geographical
setting where the prevalence of MDR-TB among new patients exceeds 3%.25 A
MDR-TB prevalence of 11.7% in 2007 among new TB cases at the Prince Cyril Zulu
Communicable Disease Centre should raise concerns as to whether the eThekwini
district is an MDR-TB ‘hot spot’. This finding also raises the concern that there are
most likely other districts in South Africa with high MDR-TB prevalence among new
TB cases. “Primary resistance is usually 5% or less in good National programmes” 19
The findings of this study imply that there is deterioration in the performance of the
TB control programme at the Prince Cyril Zulu Communicable Disease Centre and in
the eThekwini district. There is an urgent need to address the issues of infection




The finding that age was not significantly associated with MDR-TB was similar to the
South African national survey of tuberculosis drug resistance and the Durban
study.25, 26  The multivariate analysis finding that among previously treated TB cases,
the risk of MDR-TB increased as age increased is supported by the survey of 11
countries 6 where patients aged 35 to 44 years and 55 to 64 years were more likely
to have MDR-TB.6 This implies that for new TB cases age is not a risk factor for
MDR-TB and this can be generalized for Durban. However a history of previous TB
treatment increased the risk of MDR-TB for patients older that 46 years (OR 2.0;
95% CI: 1.1 to 3.0; p = 0.03) (Table 6).
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5.3.2. Sex
Sex was not significantly associated with MDR-TB. This finding was the same as the
South African national survey of tuberculosis drug resistance and several other
studies.6,25,26,27 This differed from the WHO regions were MDR-TB was associated
with the male sex.21 The similarity of the results to the South African national survey
implies that the results could only be generalized for South Africa, but not for other
countries. Sex was not a confounder for MDR-TB.
5.3.3. Race
The finding that MDR-TB was not significantly associated with any race group was
the same as the Durban study.26 The proportion of MDR-TB among the different
race groups was in keeping with the demographic characteristics of the eThekwini
district were 68% of the population were African, 20% Indian, 9% White and 3%,
Coloured. The importance is that the results of this study can then be generalized for
Durban. This implies that, if living in Durban, the risk of getting MDR-TB is the same
across the different race groups.
5.3.4. Geographical Area
This study was unable to establish an association between MDR-TB and
geographical area. This finding was similar to the findings of a study in India. 7 The
fact that 65% of MDR-TB cases come from the South Sub-district of eThekwini is
due to the fact that the Prince Cyril Zulu Communicable Disease Centre is located in
the South Sub-district.  The South Sub-district is also the largest sub district in the




Employment status was not significantly associated with MDR-TB. However, 65% of
MDR-TB cases and 64% of drug susceptible TB cases were unemployed. A study at
a TB referral hospital in Durban found that 58.2% (n = 1209) of MDR-TB patients
were unemployed and 22.9% (n = 1209) were employed41. Unemployment rates
were high among MDR-TB patients in Durban. “Deteriorating socioeconomic
conditions” 44 was identified as a contributor to the worsening TB epidemic in South
Africa. “A poor diet”12 was also implicated in the development of active MDR-TB.
Unemployment does not necessarily reflect poor diet or socioeconomic status but
these aspects could be closely related and can suggest the need for further research
in this area.
5.4. REFERRAL TYPE
There was no significant association between MDR-TB and the type of referral
namely: self referral, private sector, public hospital and primary health clinic. This
finding differed from the findings of 2 South African and a Brazilian study which
found that prior hospitalization was significantly associated with MDR-TB.25, 32, 40
This finding refutes the possible explanation that the high prevalence of MDR-TB at
this facility  is because of referrals from hospitals and primary health clinics. The
same proportion of MDR-TB cases were from hospital, 30% (n= 445) and self
referrals, 30% (n = 445). The private sector was not included in the South African
national survey. Information on MDR-TB in the private sector is limited or non-
existent. The finding that 8.5% (n = 445) of MDR-TB cases were referred from the
private sector suggest that MDR-TB is prevalent in the private sector and the private
sector should be included in the surveillance of MDR-TB.
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5.5. HIV STATUS
There was no significant association between HIV and MDR-TB. This finding was
similar to the systematic review of 32 studies which included 3 South African
studies.5, 34 It is a concern that for a large proportion of MDR-TB cases (75%) the
HIV status was unknown. HIV was not a confounder for MDR-TB. The case-fatality
among patients co-infected with HIV and MDR-TB is 72 to 89%.5 Having a high
number of MDR-TB patients with unknown HIV status would delay the
commencement of anti-retroviral therapy and contribute to the morbidity and
mortality associated with MDR-TB and HIV co-infection.
The MDR-TB prevalence was high among new TB cases in 2007 (11.7%). The
evidence shows that HIV is  associated with primary MDR-TB.5 It was not possible to
do a breakdown of HIV status between MDR-TB among new TB cases and MDR-TB
among  previously treated TB cases because of the small number of MDR-TB cases
with a known HIV status.
5.6. PREVIOUS TB
5.6.1. Previous TB Treatment
Many studies have demonstrated that previous TB treatment was an important
predictor of MDR-TB.25, 26, 31, 32, 33 This study found that there was no significant
association between previous TB treatment and MDR-TB.  A possible explanation
for this could be that some patients may have received previous TB treatment but
were misclassified as not having had previous TB treatment. “Patients don’t always
reveal previous TB treatment history”25 Information on previous TB treatment was
collected as part of the routine data collection at the Prince Cyril Zulu Communicable
Disease Centre, and not by trained research interviewers so misclassification could
have occurred. The misclassification bias was not quantified. The assumption was
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made that misclassification of previous treatment would be minimal as majority of
patients previous TB records would be available to confirm previous TB treatment.
5.6.2. Previous TB Treatment Outcome
A previous TB treatment outcome of treatment failure was significantly associated
with MDR-TB. This finding was similar to the South African national survey and the
study on South African gold miners.25, 33 A surprising finding was that a previous TB
treatment outcome of treatment default was not significantly associated with MDR-
TB.  This differed from most literature and the South African national survey on drug
resistance. 25 An unexpected finding which is contrary to current evidence on MDR-
TB was that a previous TB treatment outcome of cured was significantly associated
with MDR-TB.  The most likely explanation for these contrary findings would be
misclassification of previous TB treatment outcomes.
The survey of tuberculosis drug resistance KwaZulu-Natal survey reported, that “a
considerable proportion of patients seemed to be misclassified by the routine health
services”.35 The consequence of misclassification would be that misclassified
patients would receive the wrong treatment regimen. 35
Another explanation for the finding could be that although many MDR-TB cases
were previously treated for TB their current MDR-TB was due to exogenous re-
infection (primary resistance) and was not the result of inadequate drug therapy
(acquired resistance). Therefore the previous TB treatment outcome would have no
relation with the current TB and MDR-TB infection.
The Prince Cyril Zulu Communicable Disease Centre is in a Province with highest
TB caseload15 and a high prevalence of HIV. The exogenous re-infection possibility
is supported by the study conducted in KwaZulu-Natal which confirmed that 74% of
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previously treated TB patients developed MDR or XDR-TB as a result of exogenous
re-infection (primary resistance). 38
5.6.3. Duration of Previous TB Treatment
A duration of previous TB treatment of greater than 32 weeks was significantly
associated with MDR-TB (OR 2.0; 95% CI: 1.2 to 3.3; p = 0.005) (Table 5).  This
finding was similar to a study involving 11 countries which found that as the total
duration of prior tuberculosis treatment increased so to did the likelihood of having
MDR-TB.6 That study showed that receiving TB drugs for a period of time greater
than 6 months increased the risk of MDR-TB. 6 It was found that 27% (n = 302) of
MDR-TB cases at the Prince Cyril Zulu Communicable Disease Centre received
more than 32 weeks of TB treatment during the previous episode of TB. The TB
control programme recommends 24 weeks of TB treatment for new TB cases and 32
weeks of TB treatment for re-treatment cases.  The Prince Cyril Zulu Communicable
Disease Centre, while adhering to these recommendations, does extend TB
treatment beyond the recommended duration if there is radiological evidence that
the TB has not fully resolved. In these situations TB treatment is extended even if
sputum analysis indicates cure.
5.6.4. Duration of Previous TB Treatment Interruption
The duration of previous TB treatment interruption was not significantly associated
with MDR-TB.  No current literature was found which investigated the duration of
previous TB treatment interruption, therefore the finding of this study could not be
compared with other studies.  For the Prince Cyril Zulu Communicable Disease
Centre, this finding, together with the finding that previous TB treatment default was
not significantly associated with MDR-TB, may suggest that although treatment
adherence should remain central to TB control, this strategy alone may be
insufficient to stop the increase in MDR-TB.
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5.7. MDR-TB TIMELINES
5.7.1. Time from previous TB to MDR-TB diagnosis
The Kaplan- Meier curve demonstrated that 75% (n = 212) of MDR-TB cases
developed MDR-TB within 1092 days from the previous. The results imply that the
probability of getting MDR-TB after previous TB decreases with time. There was no
literature available on time from previous TB to MDR-TB diagnosis.
5.7.2. Time from current TB diagnosis to MDR-TB diagnosis
The median time from current TB diagnosis to MDR-TB diagnosis was 98 days. The
duration of the process of sputum culture and sensitivity to confirm MDR-TB is 6
weeks (42 days) 46 This is similar to other laboratories in South Africa, where most
commonly used culture and drug susceptibility testing methodologies require 6 to 8
weeks for results. 40 The Inkosi Albert Luthuli Laboratory informs the Prince Cyril Zulu
Communicable Disease Centre immediately when resistance to isoniazid and
rifampicin is detected. If sputum was sent for culture and sensitivity at the time of TB
diagnosis then the majority of MDR-TB cases would have been diagnosed by 42
days. The median time was 98 days from current TB diagnosis to MDR-TB
diagnosis. This result implies that 50% of MDR-TB cases did not have sputum sent
for culture and sensitivity at the time of TB diagnosis. This implies that 50% (n =
445) of the MDR-TB patients had sputum sent for culture and sensitivity at their 2
month follow up visit. Indications for sending a sputum specimen for culture and
sensitivity at a 2 month follow-up visit would have been; radiological deterioration or
a 2 month positive smear. “Delays in diagnosis lead to clinical deterioration of
patients and ongoing drug-resistant TB transmission in the community or hospital.” 40
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5.7.3. Time from MDR-TB diagnosis to MDR-TB treatment
MDR-TB patients waited a median time of 10 days from MDR-TB diagnosis to MDR-
TB treatment. This delay is due to the lack of beds for admission of patients to the
MDR-TB referral hospital for MDR-TB treatment initiation. This reason for delay in
MDR-TB treatment commencement is also experienced in other countries where
there is also “insufficient hospital capacity and long waiting lists for treatment.” 43. A
study at a MDR-TB referral hospital in Durban did Kaplan–Meier curves for time from
XDR-B diagnosis to XDR-TB treatment initiation. 45 The median time between
diagnosis and initiation of therapy for patients who died was 88days, the median
time between diagnosis and initiation of therapy for patients who survived was120
days. 45 Comparatively, a median time of 10 days from MDR-TB diagnosis to MDR-
TB treatment may not appear to be long, however in the context of the situation
where these patients are not isolated, it raises the concern of increased risk of MDR-
TB transmission. This concern is supported by literature which confirms that
appropriate isolation of suspected MDR-TB cases until disproved or appropriately
treated is important because of nosocomial and community outbreaks. 11
5.7.4. Time from current TB diagnosis to death
The time from MDR-TB diagnosis to death was not calculated. This was because of
the study design (nested case control), the results of the study found that 46% of the
27 deaths among the MDR-TB cases had occurred before bacteriological
confirmation of the MDR-TB. Deaths before confirmation of MDR-TB has been
documented elsewhere, “Overall outcomes are substantially worsened with HIV co-
infection, largely owing to very high mortality in both MDR and XDR tuberculosis
within the first 2 months, before patients can be diagnosed and started on
treatment.” 43
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The finding that 25% of deaths among the MDR-TB cases occurred within 29 days
from TB diagnosis and 50% of deaths occurred within 87 days from TB diagnosis
suggests that the progression to death in untreated MDR-TB cases is short. Survival
times for MDR-TB were not found, but the literature on survival times for XDR-TB
showed that the median survival from the time of sputum collection to death was 16
days (IQR 6 – 37) 42
A comparison of the median time from current TB diagnosis to MDR-TB diagnosis of
98 days with the median time from current TB diagnosis to death of  87 days,
together with the finding that  46% (n = 27) of deaths occurred before bacteriological
confirmation of MDR-TB shows that MDR-TB patients are dying before the diagnosis
of MDR-TB. This raises the concern that other TB deaths may be MDR –TB related
and may be occurring before MDR-TB was suspected because not all new TB cases
have sputum sent for culture and sensitivity at the time of TB diagnosis. The current
TB guidelines for South Africa do not recommend sputum culture for all TB
patients.15The results of his study support the need for sputum culture for all TB
patients in areas where the MDR-TB prevalence among new TB cases is high (>
3%). “To provide universal drug susceptibility testing for all patients with suspected
tuberculosis,” has been identified as an important strategy to prevent new cases and
manage existing cases of MDR-TB. 43 The challenge that routine cultures for all TB
suspects is not feasible due to limited laboratory capacity and cost is known.  40
However, in view of the high costs of MDR-TB, resources need to be allocated to
establish laboratory capacity capable of undertaking culture and drug susceptibility
testing for all TB patients to ensure early diagnosis, and to assess prevalence of
drug resistance, in resource limited settings. 42
The finding that 25% of deaths among MDR-TB cases occurred within 29 days of TB
diagnosis supports the concern that many TB deaths among new TB cases may be
MDR-TB related and may be occurring before MDR-TB was suspected or
diagnosed. These deaths would also be missed cases of MDR-TB. They would
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contribute to the increased transmission of MDR-TB in the community. Missed cases
of MDR-TB imply that there is underestimation of the prevalence of MDR-TB.
5.8. MDR-TB FOLLOW-UP OUTCOMES
The outcomes of the MDR-TB diagnosis at the Prince Cyril Zulu Communicable
Disease Centre could not be compared to other studies because what was
presented in this study was not the MDR-TB treatment outcome but the follow-up
outcome of each patient diagnosed with MDR-TB until MDR-TB treatment
commencement.  Although it could be confirmed that only 43% (n = 445) of patients
diagnosed with MDR-TB commenced MDR-TB treatment at the MDR-TB referral
hospital, it is possible that many of the 23% (n = 445) of patients who were lost to
study follow-up because they were moved or transferred to other facilities, did
actually commence treatment for MDR-TB. The staff at the Prince Cyril Zulu
Communicable Disease Centre ensure that bacteriological results of drug resistance
are forwarded to the facilities to which patients have been transferred.11 This
however, cannot be quantified and the possibility that a proportion of these patients
could be dying at home or defaulting treatment has to be considered.
The finding that 24% (n = 445) of patients diagnosed with MDR-TB were lost to
follow-up due to the fact that the patients defaulted from TB treatment was similar to
the findings of a study at a MDR-TB referral hospital in Durban where 21% (n =
1209) on MDR-TB treatment defaulted from treatment. 41 High defaulter rates for
drug susceptible TB and MDR-TB have most likely resulted in the creation of large
numbers of drug resistant strains. 41 It has been recommended that to reduce the
number of MDR-TB patients defaulting, decentralization of MDR-TB treatment
should be considered, by creating community- based treatment programmes or
satellite in-patient centres. 41 The benefit of decentralization of MDR-TB treatment is
11 Information obtained from the manager of the Prince Cyril Zulu Communicable Disease Centre. It is
routine procedure that medical staff at the Prince Cyril Zulu Communicable Disease Centre forward
bacteriological results of drug resistance to the facilities to which patients have been transferred.
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that it will reduce the current patient load at MDR-TB referral hospitals and therefore
reduce the delays in MDR-TB treatment initiation.
The finding that 7% of MDR-TB cases died before they started MDR-TB treatment is
concerning because patients are waiting a median time of 10 days from MDR-TB
diagnosis to commencing MDR-TB treatment.  This raises the issue of whether
MDR-TB patients are dying because of delays in receiving treatment for MDR-TB.
The Prince Cyril Zulu Communicable Disease Centre does not initiate MDR-TB
treatment.  MDR-TB patients are referred to the designated MDR-TB referral
hospital in the district for commencement of MDR-TB treatment. The Prince Cyril
Zulu Communicable Disease Centre is only able to refer MDR-TB patients for
commencement of MDR-TB treatment when there are beds available at the MDR-TB
referral hospital.  The delay in commencement of MDR-TB treatment is therefore
due to the lack of availability of beds at the MDR-TB referral hospital.
.
5.10. LIMITATIONS
 Information bias may have occurred and could have been responsible for
misclassification of previous TB treatment. It is possible that patients did not
reveal that they had previous TB treatment if they had not completed their
previous TB treatment. The reason for this would have been to avoid a
negative reaction from the healthcare worker obtaining the history.
Information bias was reduced by cross checking information obtained from
patients current visit with records from patients previous visits to the Prince
Cyril Zulu Communicable Disease Centre.
 Death before diagnosis was included in the analysis and may have been
contributed to possible bias.
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 The results on MDR-TB prevalence from this study are limited to the Prince
Cyril Zulu Communicable Disease Centre. The prevalence results do not
reflect the prevalence of MDR-TB for the province or other cities in South
Africa. However due to the high number of TB patients seen at this facility,
these results could be generalized to the eThekwini district.
 The waiting times for MDR-TB diagnosis and MDR-TB treatment
commencement are limited to the Prince Cyril Zulu Communicable Disease
Centre as they are dependent on the laboratory and MDR-TB referral hospital
used by this facility. Other facilities using the same laboratory and hospital
may be experiencing similar delays but these delays do not reflect the
situation in other areas in the Province or in South Africa.
5.10. CHAPTER SUMMARY
The important issues arising from the discussion of the results are that there are
delays in the diagnosis of MDR-TB at the Prince Cyril Zulu Communicable Disease
Centre. Patients diagnosed with MDR-TB are experiencing further delays before
MDR-TB treatment is commenced. Due to the delayed diagnosis and lack of
isolation, patients spent more than 100 days in the community with MDR-TB. This
was probably the main contributor to the spread of MDR-TB among new TB cases in
the eThekwini District and was most likely responsible for the significant increase in
prevalence of MDR-TB among new TB cases at the Prince Cyril Zulu Communicable
Disease Centre in 2007. It is a concern that the prevalence of MDR-TB among new
TB cases was 11.7% at the Prince Cyril Zulu Communicable Disease Centre in 2007
when the national prevalence of MDR-TB among new TB cases in South Africa was
1.8% in 2007. Recommendations to address some of the findings and concerns
raised will be provided in the next chapter.
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CHAPTER 6. CONCLUSIONS AND RECOMMENDATIONS
6.1. INTRODUCTION
This chapter provides the conclusions of the study based on the findings and
discussion presented in the previous two chapters. Recommendations to reduce the
transmission and spread of MDR-TB are offered to the Prince Cyril Zulu
Communicable Disease Centre and to the TB control programme. Suggestions for
further research are also made.
6.2. CONCLUSIONS
The most important finding of this study was that the Prince Cyril Zulu
Communicable Disease Centre experienced an increase in the prevalence of MDR-
TB in 2007 which was largely due to a significant increase in prevalence of MDR-TB
among new TB cases. The MDR-TB prevalence was 11.7% among new TB cases
and 4.7% among previously treated TB cases in 2007. The study found that there
was no significant association between demographic characteristics and MDR-TB.
There was no significant association between HIV status and MDR-TB. The
subgroup analysis of patients with previous TB found that there was a significant
association with a previous TB treatment outcome of treatment failure and MDR-TB.
A duration of previous TB treatment of greater than 32 weeks was also found to be
significantly associated with MDR-TB. Among MDR-TB patients with previous TB,
age > 46 years was significantly associated with MDR-TB. There were delays in the
diagnosis of MDR-TB at the Prince Cyril Zulu Communicable Disease Centre.
Patients diagnosed with MDR-TB were waiting a median time of 10 days before
MDR-TB treatment was commenced. Due to the delayed diagnosis and lack of
isolation, patients spent over 100 days in the community with MDR-TB. This was
probably the main contributor to the spread of MDR-TB in the eThekwini District. It
was confirmed that 43% of MDR-TB cases commenced MDR-TB treatment, 23% of
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the cases were lost to study follow-up because the patients were moved or
transferred to another facility, 24% of the cases were lost to follow-up because the
patients defaulted from TB treatment before the MDR-TB diagnosis was made and
7% of MDR-TB cases died before they started MDR-TB treatment. The Prince Cyril
Zulu Communicable Disease centre needs to take urgent steps to reduce the delays
in diagnosis of MDR-TB, reduce the waiting time for MDR-TB treatment
commencement and improve infection control measures to reduce the spread of
MDR-TB.
Recommendations to the Prince Cyril Zulu Communicable Disease Centre and TB
control programme to reduce the spread of MDR-TB will follow.
6.3. RECOMMENDATIONS
6.3.1. Recommendations for Prince Cyril Zulu Communicable Disease Centre
 The Prince Cyril Zulu Communicable Disease Centre should develop a
routine monitoring system to determine the incidence and prevalence of
MDR-TB at the facility on an annual basis. This should include distinguishing
between primary and acquired drug resistance so that emphasis can be
placed on the appropriate strategy to address the drug resistance problem. If
the majority of the cases of MDR-TB develop as a result of acquired
resistance then emphasis must be placed on strengthening directly observed
treatment short course (DOTS) and improving treatment cure rates. If primary
resistance is a major factor then the creation and implementation of infection
control measures at household and community level must be added as a
critical component of the control strategy in order to curb the ongoing
transmission of drug resistant strains.38 The responsibility for this intervention
lies with the Prince Cyril Zulu Communicable Disease Centre manager and
with the eThekwini District TB Control Programme coordinator.
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 In response to the MDR-TB prevalence of 11.7% among new TB cases the
Prince Cyril Zulu Communicable Disease Centre should consider performing
sputum culture and sensitivity on all new TB cases. This would prevent delays
in MDR-TB diagnosis and MDR-TB treatment commencement.
 In response to the delays in diagnosing MDR-TB the Prince Cyril Zulu
Communicable Disease Centre should in conjunction with the TB culture
laboratory explore other options to detect TB drug resistance in a shorter time
instead of waiting six weeks for culture and sensitivity results. An option that
could be considered is the Line Probe Assay which is used for smear positive
sputum and determines resistance to isoniazid and rifampicin in 24 hours (Not
in use at the Inkosi Albert Luthuli TB Laboratory in 2007). An alternative
option is the Gene Expert which could be used for sputum that is smear
positive or negative and determines resistance to rifampicin in two hours.
 Isolation of MDR-TB patients at other hospitals while awaiting MDR-TB
treatment commencement is an appropriate recommendation but unlikely to
be practical due to resource constraints and the lack of availability of beds in
public hospitals. Therefore improving and ensuring patient education on basic
infection control measures for MDR-TB patients is essential. Measures should
include: safe coughing and sputum disposal, separate sleeping place,
ventilation and sunlight. Some consideration should be given to the issuing of
masks to patients for home use to reduce the spread of infection.
 In view of the delays in the commencement of MDR-TB treatment, the Prince
Cyril Zulu Communicable Disease Centre should consider commencing MDR-
TB treatment at the facility on an out-patient basis for selected patients who
are at a lower risk for complications. This could be done if a doctor from the
MDR-TB referral hospital rotated through the Prince Cyril Zulu Communicable
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Disease Centre and initiated MDR-TB patients on MDR-TB treatment as out
patients or the doctors at the Prince Cyril Zulu Communicable Disease Centre
could be trained on MDR-TB treatment. The latter option may be more
feasible.
 Accelerate voluntary counselling and testing programmes for HIV to ensure
that all TB and MDR-TB cases are tested for HIV. To ensure that all MDR-TB
cases are commenced on anti-retroviral therapy as recommended by the
South African HIV treatment guidelines. The integration of HIV and TB service
should be prioritized.
 Training of staff on obtaining more accurate information with regard to
previous TB treatment and previous TB treatment outcome.
 The National Tuberculosis Control Programme (NTCP) Guidelines stipulate
that TB treatment should be for six months. This study has shown that
treatment longer than 32 weeks increases the risk of MDR-TB significantly,
Prince Cyril Zulu Communicable Disease Centre must treat TB patients
according to the TB guidelines,
 Ensure that all TB treatment defaulters are traced with special emphasis on
tracing defaulters who have sputum confirmed MDR-TB. These defaulters
should be encouraged to return to the Prince Cyril Zulu Communicable
Disease Centre for appropriate counselling on MDR-TB even if they refuse
treatment.
 Strengthen and improve directly observed treatment short course (DOTS) to
ensure patient adherence to treatment and improve cure rates.
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6.3.2. Recommendations for the TB control programme
 The South African TB control programme should encourage all facilities to
monitor their MDR-TB incidence and prevalence in order to detect changes in
trends and to determine ‘hot spots’ where the MDR-TB prevalence among
new TB cases exceeds 3%.
 It is suggested that for those facilities were the MDR-TB prevalence among
new TB cases exceeds 3% all new TB cases must have sputum culture and
sensitivity performed. This would prevent delays in MDR-TB diagnosis and
MDR-TB treatment commencement.
 In view of the delays in the commencement of MDR-TB treatment due to the
lack of availability of beds at the MDR-TB referral hospital the South African
TB control programme should consider increasing the number of MDR-TB
referral hospitals providing MDR-TB treatment in the eThekwini district to
reduce the waiting times for MDR-TB treatment. Alternatively, consideration
should be given to the use of community based injection teams in the
eThekwini district were the need for MDR-TB treatment is high and the MDR-
TB referral hospital is unable to cope with the demand for beds.
6.3.3. Recommendations for further research
 Further investigation should be conducted at the Prince Cyril Zulu
Communicable Disease Centre to determine what the continued trend in
MDR-TB prevalence among new TB cases was from 2008 to 2010.
 Future investigations and surveillance activities should be extended to include
the incidence of MDR-TB in addition to the prevalence of MDR-TB.
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 MDR-TB prevalence studies should be conducted in the private sector and
the private sector must be included in all drug resistance surveillance.
 A study to determine the role of exogenous re-infection as a cause of MDR-
TB among previously treated TB cases will provide important information on
the mechanism of MDR-TB at the Prince Cyril Zulu Communicable Disease
Centre. This would enable the implementation of appropriate strategies to
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